


# World Journal of *Biological Chemistry*

World J Biol Chem 2012 May 26; 3(5): 93-109



## Editorial Board

2009-2013

The *World Journal of Biological Chemistry* Editorial Board consists of 529 members, representing a team of worldwide experts in biochemistry and molecular biology. They are from 40 countries, including Argentina (1), Australia (7), Austria (2), Belgium (6), Brazil (5), Bulgaria (1), Canada (18), Chile (1), China (36), Czech Republic (1), Denmark (1), Finland (3), France (14), Germany (17), Greece (4), India (9), Iran (2), Israel (5), Italy (26), Japan (43), Lithuania (1), Mauritius (1), Mexico (2), Netherlands (7), New Zealand (2), Norway (4), Portugal (4), Romania (1), Russia (2), Singapore (5), South Africa (1), South Korea (19), Spain (18), Sweden (4), Switzerland (2), Thailand (2), Turkey (1), Ukraine (1), United Kingdom (19), and United States (231).

### EDITOR-IN-CHIEF

Yin-Yuan Mo, *Springfield*

### STRATEGY ASSOCIATE

#### EDITORS-IN-CHIEF

Christine Blattner, *Karlsruhe*

Steven Howard Caplan, *Omaha*

Sic L Chan, *Orlando*

Shiyou Chen, *Athens*

Wen-Xing Ding, *Kansas*

Huabei Guo, *Athens*

ShouWei Han, *Atlanta*

Takashi Kuzuhara, *Tokushima*

Benfang Lei, *Bozeman*

Giuseppe Lippi, *Verona*

Hui-Yu Liu, *Research Triangle Park*

Emil Martin, *Houston*

Tadahiro Numakawa, *Tokyo*

Takashi Okamoto, *Nagoya*

Jeremy G Richman, *San Diego*

Noula D Shembade, *Miami*

### GUEST EDITORIAL BOARD

#### MEMBERS

Woei-Jer Chuang, *Tainan*

Shie-Liang Hsieh, *Taipei*

Wen-Chun Hung, *Tainan*

Ya-Mei Bai, *Taipei*

Ming-Chieh Ma, *Hsinchung*

Tang-Long Shen, *Taipei*

### MEMBERS OF THE EDITORIAL BOARD



**Argentina**

María I Vaccaro, *Buenos Aires*



**Australia**

Beric Henderson, *Sydney*

Maria Hrmova, *Adelaide*

Tao Liu, *Sydney*

Brett A Neilan, *Sydney*

Jiake Xu, *Perth*

Hongyuan Yang, *Sydney*

Hong Zhou, *Sydney*



**Austria**

Dubravko Rendic, *Vienna*

Guenther Witzany, *Buermoos*



**Belgium**

Han Asard, *Antwerp*

Rudi Beyaert, *Ghent*

Zeger Debyser, *Leuven*

Robert Kiss, *Brussels*

Ghislain Opendakker, *Leuven*

Dirk Saerens, *Brussel*



**Brazil**

Vasco Azevedo, *Belo Horizonte*

Eliana Barreto-Bergter, *Rio de Janeiro*

Jörg Kobarg, *Campinas*

M da Graça Naffah-Mazzacoratti, *São Paulo*

André LS Santos, *Rio de Janeiro*



**Bulgaria**

Zdravko Lalchev, *Sofia*



**Canada**

Abedelnasser Abulrob, *Ottawa*

Ala-Eddin Al Moustafa, *Montreal*

Annie Angers, *Montreal*

Miodrag Belosevic, *Edmonton*

Sirano Dhe-Paganon, *Ontario*

Eleftherios P Diamandis, *Toronto*

Sheng-Tao Hou, *Ottawa*

Simon Labbé, *Sherbrooke*

Hoyun Lee, *Sudbury*

Olivier Lesur, *Sherbrooke*

Gang Li, *Vancouver*

Rongtuan Lin, *Montreal*

Hongyu Luo, *Montreal*

Jean-Pierre Perreault, *Sherbrooke*

Marco AM Prado, *London*

Patrick Provost, *Quebec*

Zhiguo Wang, *Montreal*

Xiaolong Yang, *Kingston*



**Chile**

Enrique Brandan, *Casilla*



**China**

Raymond Cheung, *Hong Kong*

Stephen Chung, *Hong Kong*

Jing-Yuan Fang, *Shanghai*

Jun-Ming Guo, *Ningbo*  
 Chang-Jiang Jin, *Hefei*  
 Dong-Yan Jin, *Hong Kong*  
 Hui-Hua Li, *Beijing*  
 Chun Liang, *Hong Kong*  
 Feng Liu, *Nanjing*  
 Shu-Wen Liu, *Guangzhou*  
 Pei-Yuan Qian, *Hong Kong*  
 Lei Ren, *Xiamen*  
 Hong-Bo Shao, *Yantai*  
 Tao Tao, *Xiamen*  
 Karl Tsim, *Hong Kong*  
 Paulus S Wang, *Taipei*  
 Ling-Yun Wu, *Beijing*  
 Zhi-Heng Xu, *Beijing*  
 Yong-Bin Yan, *Beijing*  
 Tang-Bin Yang, *Beijing*  
 Zeng-Ming Yang, *Xiamen*  
 Xue-Wu Zhang, *Guangzhou*  
 Yiguo Zhang, *Chongqing*  
 Hai-Meng Zhou, *Beijing*  
 Rong-Jia Zhou, *Wuhan*  
 Xiao-Feng Zheng, *Beijing*  
 Wei-Guo Zhu, *Beijing*  
 Chao-Chun Zou, *Hangzhou*  
 Shan Cen, *China*



#### Czech Republic

Petr Draber, *Prague*



#### Denmark

Rasmus Hartmann-Petersen, *Copenhagen*



#### Finland

Ville-Petteri Mäkinen, *Helsinki*  
 Mikko Juhani Nikinmaa, *Turku*  
 Mika Rämet, *Tampere*



#### France

Yannick Allanore, *Paris*  
 Olivier Bertheau, *Jouy En Josas*  
 Jean-Yves Bouet, *Toulouse*  
 Anthony William Coleman, *Lyon*  
 Cristine Alves da Costa, *Valbonne*  
 Yannick Goumon, *Strasbourg*  
 Herve Hoste, *Toulouse*  
 Anne Imberty, *Grenoble*  
 Eric J Kremer, *Montpellier*  
 Florian Lesage, *Sophia-Antipolis*  
 Jean-Louis Mergny, *Lyon*  
 Sylvie Rebuffat, *Paris*  
 Norbert Rolland, *Grenoble*  
 Sandrine Sagan, *Paris*



#### Germany

Maik Behrens, *Nuthetal*  
 Matthias Eckhardt, *Bonn*  
 Harald Genth, *Hannover*  
 Martin Gotte, *Muenster*  
 Christian Hallermann, *Muenster*  
 Michael Hecker, *Greifswald*  
 Bernhard Lüscher, *Aachen*

Werner Müller, *Mainz*  
 Jörg Nickelsen, *Planegg-Martinsried*  
 Wolfgang Obermann, *Bochum*  
 Matthias Ocker, *Marburg*  
 Satish Raina, *Borstel*  
 Michael Ristow, *Jena*  
 M Lienhard Schmitz, *Giessen*  
 Klaus Schulze-Osthoff, *Tübingen*  
 Gerhild van Echten-Deckert, *Bonn*



#### Greece

Evangelia Papadimitriou, *Patras*  
 Maria Papagianni, *Thessaloniki*  
 Georgia Sotiropoulou, *Rion-Patras*  
 Niki Chondrogianni, *Athens*



#### India

Subrata Chattopadhyay, *Mumbai*  
 Virendra S Gomase, *Latur*  
 Siddhartha S Jana, *Kolkata*  
 Sunil Kumar Manna, *Hyderabad*  
 Vinay K Nandicoori, *New Delhi*  
 MN Ponnuswamy, *Chennai*  
 Manoj Raje, *Chandigarh*  
 Shio Kumar Singh, *Varanasi*  
 TP Singh, *New Delhi*



#### Iran

Mehrdad Mohri, *Mashhad*  
 Seyed Nasser Ostad, *Tehran*



#### Israel

Shoshana Bar-Nun, *Tel Aviv*  
 Shaul Mordechai, *Beer Sheva*  
 Zvi Naor, *Tel Aviv*  
 Eitan Shaulian, *Jerusalem*  
 Varda Shoshan-Barmatz, *Beer Sheva*



#### Italy

Andrea Battistoni, *Rome*  
 Annamaria Bevilacqua, *Milan*  
 Antonio Brunetti, *Catanzaro*  
 Santina Bruzzone, *Genova*  
 Gaetano Cairo, *Milano*  
 Giovanna De Chiara, *Rome*  
 Rita De Santis, *Pomezia*  
 Rosario Donato, *Perugia*  
 Vittorio Gentile, *Naples*  
 Fabio Grizzi, *Milan*  
 Maria Luisa Mangoni, *Rome*  
 Luca Munaron, *Torino*  
 Antonio Musarò, *Rome*  
 Sergio Papa, *Bari*  
 Alberto Passi, *Varese*  
 Rinaldo Pellicano, *Turin*  
 Luca Rampoldi, *Milan*  
 Andrea Rasola, *Padova*  
 Gianfranco Risuleo, *Rome*  
 Vito Ruggiero, *Pomezia*

Roberto Scatena, *Rome*  
 Massimo Stefani, *Florence*  
 Andrea Trabocchi, *Florence*  
 Carlo Ventura, *Bologna*  
 Elena Zocchi, *Genova*



#### Japan

Naohiko Anzai, *Tokyo*  
 Noriko Fujiwara, *Nishinomiya*  
 Yoshiaki Furukawa, *Yokohama*  
 Hiroshi Harada, *Kyoto*  
 Makoto Hashimoto, *Tokyo*  
 Tadashi Hatanaka, *Kaga-gun*  
 Eiichi Hinoi, *Kanazawa*  
 Satoshi Inoue, *Tokyo*  
 Takaki Ishikawa, *Osaka*  
 Yoshizumi Ishino, *Fukuoka*  
 Hiroaki Itamochi, *Yonago*  
 Hideaki Kaneto, *Osaka*  
 Koichi Kato, *Okazaki*  
 Eiichi N Kodama, *Sendai*  
 Kenji Kuwasako, *Miyazaki*  
 Katsumi Maenaka, *Fukuoka*  
 Hisao Masai, *Tokyo*  
 Shin-Ichiro Miura, *Fukuoka*  
 Eiji Miyoshi, *Suita*  
 Ryuichi Morishita, *Suita*  
 Yasu S Morita, *Osaka*  
 Tatsuya Sakamoto, *Setouchi*  
 Toshiyasu Sasaoka, *Toyama*  
 Hiroshi Shibuya, *Bunkyo*  
 Toru Shimizu, *Sendai*  
 Hiroshi Takahashi, *Tottori*  
 Takashi Takeuchi, *Yonago*  
 Tomohiro Tamura, *Sapporo*  
 Kengo Tanabe, *Tokyo*  
 Takuji Tanaka, *Gifu*  
 Ikuo Tooyama, *Otsu*  
 Hirokazu Tsukahara, *Fukui*  
 Toshimitsu Uede, *Sapporo*  
 Nobutaka Wakamiya, *Asahikawa*  
 Ji-Yang Wang, *Yokohama*  
 Richard W Wong, *Kanazawa*  
 Sho-Ichi Yamagishi, *Kurume*  
 Michiaki Yamashita, *Yokohama*  
 Kiyotsugu Yoshida, *Tokyo*  
 Tsutomu Mikawa, *Yokohama*



#### Lithuania

Arunas Ramanavicius, *Vilnius*



#### Mauritius

Theeshan Bahorun, *Reduit*



#### Mexico

Alejandra Bravo, *Morelos*  
 Gerardo Corzo, *Morelos*



#### Netherlands

Egbert J Boekema, *Groningen*  
 N Bovenschen, *Utrecht*  
 Bart Maarten Gadella, *Utrecht*  
 Leo Nijtmans, *Nijmegen*

MAM van Steensel, *Maastricht*  
Ronald JA Wanders, *Amsterdam*  
Dietbert Neumann, *Maastricht*



### **New Zealand**

Alexander V Peskin, *Christchurch*  
Christian Hartinger, *Auckland*



### **Norway**

K Kristoffer Andersson, *Oslo*  
Ugo Moens, *Tromsø*  
J Preben Morth, *Oslo*  
Herve Seligmann, *Oslo*



### **Portugal**

Manuel Aureliano, *Faro*  
Carlos Alberto da Silva Conde, *Porto*  
Carlos Bandeira Duarte, *Cantanhede*  
Ceu Figueiredo, *Porto*



### **Romania**

Anca V Gafencu, *Bucharest*



### **Russia**

Vladimir S Bondar, *Krasnoyarsk*  
Ilya V Demidyuk, *Moscow*



### **Singapore**

Sohail Ahmed, *Singapore*  
Surajit Bhattacharyya, *Singapore*  
Kah-Leong Lim, *Singapore*  
Jianxing Song, *Singapore*  
Bor Luen Tang, *Singapore*



### **South Africa**

Ugo Ripamonti, *Johannesburg*



### **South Korea**

Jae Youl Cho, *Chuncheon*  
Cheol Yong Choi, *Suwon*  
Dalwoong Choi, *Seoul*  
Hueng-Sik Choi, *Gwangju*  
Kang-Yell Choi, *Seodemun Gu*  
Sin-Hyeog Im, *Gwangju*  
Byeong-Churl Jang, *Daegu*  
Min-Seon Kim, *Seoul*  
Byoung-Mog Kwon, *Daejeon*  
Seong-Wook Lee, *Yongin*  
Sung Joong Lee, *Seoul*  
Lee Bok Luel, *Busan*  
Yuseok Moon, *Yangsan*  
Jongsun Park, *Taejeon*  
Dong Min Shin, *Seoul*  
Young-Joon Surh, *Seoul*

Kweon Yu, *Daejeon*  
Jung Weon Lee, *Seoul*  
Sung-Hoon Kim, *Seoul*



### **Spain**

Jose M Andreu, *Madrid*  
Joaquin Arino, *Cerdanyola del Valles*  
Joaquín Arribas, *Barcelona*  
Jesus Avila, *Madrid*  
Antonio Casamayor, *Cerdanyola*  
Antonio Celada, *Barcelona*  
Francisco Ciruela, *Barcelona*  
Senena Corbalan, *Murcia*  
Antonio Felipe, *Barcelona*  
Tino Krell, *Granada*  
Pedro A Lazo, *Salamanca*  
Wolfgang Link, *Madrid*  
Jorge Martín-Pérez, *Madrid*  
Faustino Mollinedo, *Salamanca*  
Guillermo Montoya, *Madrid*  
Rosario Muñoz, *Madrid*  
Julia Sanz-Aparicio, *Madrid*  
Manuel Vázquez-Carrera, *Barcelona*



### **Sweden**

Bo Åkerström, *Lund*  
Leonard Girnita, *Stockholm*  
Johan Lennartsson, *Uppsala*  
John Ulf Rannug, *Stockholm*



### **Switzerland**

Dietmar Benke, *Zürich*  
Roger Schneiter, *Fribourg*



### **Thailand**

Pimchai Chaiyen, *Bangkok*  
Veerapol Kukongviriyapan, *Khon Kaen*



### **Turkey**

Necla Çağlarımak, *Manisa*



### **Ukraine**

Eugene S Kryachko, *Kiev*



### **United Kingdom**

Per Bullough, *Sheffield*  
Wayne Grant Carter, *Nottingham*  
Marco Falasca, *London*  
Julian Leather Griffin, *Cambridge*  
Kristiina Hilden, *Nottingham*  
Adam D Hughes, *Argyll*  
Lin-Hua Jiang, *Leeds*  
Zhi-Liang Lu, *Edinburgh*  
Peter Monk, *Sheffield*  
Elizabeth Lara Ostler, *Brighton*  
Ihtesham Ur Rehman, *Sheffield*  
Eugenio Sanchez-Moran, *Birmingham*

Cliff Taggart, *Belfast*  
David J Timson, *Belfast*  
Patrick J Twomey, *Suffolk*  
Elisabetta Verderio, *Nottingham*  
Stephen Geoffrey Ward, *Bath*  
Lu-Gang Yu, *Liverpool*  
Barry Roger Barraclough, *Liverpool*



### **United States**

Ruhul Abid, *Boston*  
Nihal Ahmad, *Wisconsin*  
Stephen Alexander, *Columbia*  
Andrei T Alexandrescu, *Storrs*  
Seth L Alper, *Boston*  
Suresh V Ambudkar, *Maryland*  
Douglas Andres, *Lexington*  
Insoo Bae, *Washington*  
Scott R Baerson, *University*  
Omar Bagasra, *Orangeburg*  
Yidong Bai, *San Antonio*  
Andrei V Bakin, *Buffalo*  
Joe B Blumer, *Charleston*  
Jonathan S Bogan, *New Haven*  
Joseph T Brozinick, *Indianapolis*  
Michael Bruce Butterworth, *Pittsburgh*  
Nickolay Brustovetsky, *Indianapolis*  
Huaibin Cai, *Bethesda*  
Blanca Camoretti-Mercado, *Chicago*  
Daniel GS Capelluto, *Blacksburg*  
Subrata Chakrabarti, *Boston*  
Subbaiah C Chalivendra, *Colorado*  
Yongchang Chang, *Phoenix*  
Yung-Fu Chang, *Ithaca*  
Xian-Ming Chen, *Omaha*  
Guanjun Cheng, *Philadelphia*  
Wen-Hsing Cheng, *College Park*  
Xiaodong Cheng, *Galveston*  
Kuo-Chen Chou, *San Diego*  
John William Christman, *Chicago*  
Daret St Clair, *Lexington*  
Katalin Csiszar, *Honolulu*  
Mu-Shui Dai, *Portland*  
Siddhartha Das, *El Paso*  
John S Davis, *Nebraska*  
Channing Joseph Der, *Chapel Hill*  
Nikolay V Dokholyan, *Chapel Hill*  
Jing-Fei Dong, *Seattle*  
Zheng Dong, *Augusta*  
Sinisa Dovat, *Madison*  
Guangwei Du, *Houston*  
Penelope Duerksen-Hughes, *Loma Linda*  
Sherine Elsawa, *Rochester*  
Ahmed Faik, *Athens*  
Huizhou Fan, *Piscataway*  
Yong Fan, *Pittsburgh*  
Qingming Fang, *Pittsburgh*  
Victor Faundez, *Atlanta*  
Changjian Feng, *Albuquerque*  
Jay William Fox, *Charlottesville*  
Irwin Fridovich, *Durham*  
Yuchang Fu, *Birmingham*  
Alexandros Georgakilas, *Greenville*  
Shibnath Ghatak, *Charleston*  
Alasdair M Gilfillan, *Bethesda*  
Jeffrey M Gimble, *Baton Rouge*  
Antonio Giordano, *Philadelphia*  
Channe Gowda, *Hershey*  
Vsevolod V Gurevich, *Nashville*  
James Hagman, *Denver*

Tsonwin Hai, *Columbus*  
Yusuf A Hannun, *Charleston*  
Dee Harrison-Findik, *Omaha*  
Ian S Haworth, *Los Angeles*  
Tong-Chuan He, *Chicago*  
L Shannon Holliday, *Gainesville*  
Shangwei Hou, *Philadelphia*  
Chuanshu Huang, *Tuxedo*  
Shile Huang, *Shreveport*  
Yan Huang, *Charleston*  
Johnny Huard, *Pittsburgh*  
Hieronim Jakubowski, *Newark*  
Xinhua Ji, *Frederick*  
Yu Jiang, *Pittsburgh*  
Victor X Jin, *Columbus*  
Leis Jonathan, *Chicago*  
Dhan V Kalvakolanu, *Baltimore*  
Hung-Ying Kao, *Cleveland*  
Zvi Kelman, *Rockville*  
Bruce C Kone, *Houston*  
Rakesh C Kukreja, *Richmond*  
Jill M Lahti, *Memphis*  
Yurong Lai, *Groton*  
KH William Lau, *Loma Linda*  
Beth S Lee, *Columbus*  
Menq-Jer Lee, *Michigan*  
Suk-Hee Lee, *Indianapolis*  
Saobo Lei, *Grand Forks*  
Jianyong Li, *Blacksburg*  
Xiang-An Li, *Lexington*  
Xiaoxia Li, *Cleveland*  
Xuhang Li, *Baltimore*  
Yan Chun Li, *Chicago*  
Yefu Li, *Boston*  
Zhenyu Li, *Lexington*  
Zhuowei Li, *Durham*  
Xia Lin, *Houston*  
Chen-Yong Lin, *Baltimore*  
Chuanju Liu, *New York*  
Jianyu Liu, *Lexington*  
Lin Liu, *Stillwater*  
Youhua Liu, *Pittsburgh*  
Zheng Liu, *Albany*  
Zhi-Ren Liu, *Atlanta*  
Kun Ping Lu, *Boston*  
Zhimin Lu, *Houston*  
Victoria Lunyak, *Novato*  
Buyong Ma, *Frederick*  
Qing Ma, *Houston*  
Mark Mattson, *Baltimore*  
Bradley K McConnell, *Houston*  
Suniti Misra, *Charleston*  
Liviu Movileanu, *New York*

Dale G Nagle, *Mississippi*  
Michael Naski, *San Antonio*  
James H Nichols, *Springfield*  
Christopher M Norris, *Lexington*  
Shoichiro Ono, *Atlanta*  
Tim D Oury, *Pittsburgh*  
Caroline A Owen, *Boston*  
Qishen Pang, *Cincinnati*  
Martin Paukert, *Baltimore*  
Lee G Pedersen, *Chapel Hill*  
Luiz Otavio Penalva, *San Antonio*  
Ji-Bin Peng, *Birmingham*  
Claudio F Perez, *Boston*  
Leonidas C Platanias, *Chicago*  
Sergei Pletnev, *Chicago*  
Serguei Popov, *Manassas*  
Jun Qin, *Houston*  
Suofu Qin, *Irvine*  
Jody A Summers Rada, *Oklahoma*  
Evette S Radisky, *Jacksonville*  
Nader Rahimi, *Boston*  
Arshad Rahman, *Rochester*  
Kota V Ramana, *Galveston*  
Radhakrishna Rao, *Tennessee*  
Sekhar P Reddy, *Baltimore*  
Osvaldo Rey, *Los Angeles*  
Nikolaos K Robakis, *New York*  
Erle S Robertson, *Philadelphia*  
Rouel S Roque, *Henderson*  
Loren Runnels, *Piscataway*  
Esther L Sabban, *New York*  
Hee-Jeong Im Sampen, *Chicago*  
Richard Jude Samulski, *Chapel Hill*  
Fazlul Sarkar, *Detroit*  
Bassel E Sawaya, *Philadelphia*  
Rong Shao, *Springfield*  
Bin Shan, *New Orleans*  
Dipali Sharma, *Baltimore*  
Krishna Sharma, *Columbia*  
Xing-Ming Shi, *Augusta*  
Weinian Shou, *Indianapolis*  
Richard N Sifers, *Houston*  
Patricia J Simpson-Haidaris, *Rochester*  
Emanuel E Strehler, *Rochester*  
Jiyuan Sun, *Houston*  
Ramanjulu Sunkar, *Stillwater*  
Vishnu Suppiramaniam, *Auburn*  
Eva Surmacz, *Philadelphia*  
Ming Tan, *Mobile*  
Dean G Tang, *Texas*  
Ken Teter, *Orlando*  
Chinnaswamy Tiruppathi, *Illinois*  
Mate Tolnay, *Silver Spring*

Eric A Toth, *Baltimore*  
Yiider Tseng, *Gainesville*  
Alexander Tsygankov, *Philadelphia*  
John J Turchi, *Indianapolis*  
Robert J Turesky, *Albany*  
James Turkson, *Orlando*  
Vladimir N Uversky, *Tampa*  
Jay Vadgama, *Los Angeles*  
Sergei Vakulenko, *Notre Dame*  
Andre J van Wijnen, *Worcester*  
Chunyu Wang, *Houston*  
Hong-Gang Wang, *Hershey*  
Qin Wang, *Birmingham*  
Tianyi Wang, *Pittsburgh*  
Wei-qun Wang, *Manhattan*  
Xiang-Dong Wang, *Boston*  
Yanzhuang Wang, *Ann Arbor*  
Ying Wang, *Detroit*  
Chin-Chuan Wei, *Edwardsville*  
Lai Wei, *Bethesda*  
Lei Wei, *Indianapolis*  
Guangyu Wu, *Louisiana*  
Guoyao Wu, *College Station*  
Rui Wu, *Boston*  
Weidong Wu, *Chapel Hill*  
Yang Xia, *Texas*  
Jingwu Xie, *Indianapolis*  
Zhongjian Xie, *San Francisco*  
Huabao Xiong, *New York*  
Wen-Cheng Xiong, *Augusta*  
Yan Xu, *Indianapolis*  
Jianhua Yang, *Houston*  
Kevin J Yarema, *Baltimore*  
Jianping Ye, *Baton Rouge*  
Longde Yin, *White Plains*  
Zhong Yun, *New Haven*  
Baolin Zhang, *Bethesda*  
Chunxiang Zhang, *Newark*  
Guolong Zhang, *Stillwater*  
Jiandi Zhang, *Burlingame*  
Ming Zhang, *Chicago*  
Xin Zhang, *Memphis*  
Zhizhuang Joe Zhao, *Oklahoma*  
Jing Zheng, *Chicago*  
Guangming Zhong, *San Antonio*  
Xiaotian Zhong, *Cambridge*  
Wei Zhu, *New York*  
Ronghua ZhuGe, *Worcester*  
Chunbin Zou, *Pittsburgh*  
Hui-Ling Chiang, *Hershey*  
Salvatore V Pizzo, *Durham*  
Gary W Reuther, *Tampa*  
Alex Therien, *Kenilworth*



**Contents**

Monthly Volume 3 Number 5 May 26, 2012

**TOPIC HIGHLIGHT**      93      Peroxisomes, oxidative stress, and inflammation  
*Terlecky SR, Terlecky LJ, Giordano CR*

**ORIGINAL ARTICLES**      98      Septin 8 is an interaction partner and *in vitro* substrate of MK5  
*Shiryaev A, Kostenko S, Dumitriu G, Moens U*

**ACKNOWLEDGMENTS** I Acknowledgments to reviewers of *World Journal of Biological Chemistry*

**APPENDIX** I Meetings  
 I-V Instructions to authors

**ABOUT COVER** Shiryayev A, Kostenko S, Dumitriu G, Moens U. Septin 8 is an interaction partner and *in vitro* substrate of MK5.  
*World J Biol Chem* 2012; 3(5): 98-109  
<http://www.wjgnet.com/1949-8454/full/v3/i5/98.htm>

**AIM AND SCOPE** *World Journal of Biological Chemistry (World J Biol Chem, WJBC)*, online ISSN 1949-8454, DOI: 10.4331, is a monthly, open-access, peer-reviewed journal supported by an editorial board of 529 experts in biochemistry and molecular biology from 40 countries.  
 The major task of *WJBC* is to rapidly report the most recent developments in the research by the close collaboration of biologists and chemists in area of biochemistry and molecular biology, including: general biochemistry, pathobiochemistry, molecular and cellular biology, molecular medicine, experimental methodologies and the diagnosis, therapy, and monitoring of human disease.

**FLYLEAF** I-III Editorial Board

**EDITORS FOR THIS ISSUE**

Responsible Assistant Editor: *Jian-Xia Cheng*  
 Responsible Electronic Editor: *Dan-Ni Zhang*  
 Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Jian-Xia Cheng*

**NAME OF JOURNAL**  
*World Journal of Biological Chemistry*

**ISSN**  
 ISSN 1949-8454 (online)

**LAUNCH DATE**  
 February 26, 2010

**FREQUENCY**  
 Monthly

**EDITING**  
 Editorial Board of *World Journal of Biological Chemistry*,  
 Room 903, Building D, Ocean International Center,  
 No. 62 Dongsihuan Zhonglu, Chaoyang District,  
 Beijing 100025, China  
 Telephone: +86-10-85381892  
 Fax: +86-10-85381893  
 E-mail: [wjbc@wjgnet.com](mailto:wjbc@wjgnet.com)  
<http://www.wjgnet.com>

**EDITOR-IN-CHIEF**  
**Yin-Yuan Mo, PhD, Associate Professor, Medical**

Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL 62702, United States

**EDITORIAL OFFICE**  
 Jian-Xia Cheng, Director  
*World Journal of Biological Chemistry*  
 Room 903, Building D, Ocean International Center,  
 No. 62 Dongsihuan Zhonglu, Chaoyang District,  
 Beijing 100025, China  
 Telephone: +86-10-85381892  
 Fax: +86-10-85381893  
 E-mail: [wjbc@wjgnet.com](mailto:wjbc@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLISHER**  
 Baishideng Publishing Group Co., Limited,  
 Room 1701, 17/F, Henan Building,  
 No.90 Jaffe Road, Wanchai, Hong Kong, China  
 Fax: +852-31158812  
 Telephone: +852-58042046  
 E-mail: [bpg@baishideng.com](mailto:bpg@baishideng.com)  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
 May 26, 2012

**COPYRIGHT**  
 © 2012 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
 All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

**INSTRUCTIONS TO AUTHORS**  
 Full instructions are available online at [http://www.wjgnet.com/1949-8454/g\\_info\\_20100316155305.htm](http://www.wjgnet.com/1949-8454/g_info_20100316155305.htm)

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/1949-8454office/>

Hui-Ling Chiang, PhD, Professor, Series Editor

## Peroxisomes, oxidative stress, and inflammation

Stanley R Terlecky, Laura J Terlecky, Courtney R Giordano

Stanley R Terlecky, Laura J Terlecky, Courtney R Giordano, Department of Pharmacology, Wayne State University School of Medicine, 540 E. Canfield Ave., Detroit, MI 48201, United States  
Author contributions: Terlecky SR wrote the majority of the review; Terlecky LJ and Giordano CR contributed to the writing, designed and produced the figures, and edited the manuscript.

Correspondence to: Stanley R Terlecky, PhD, Department of Pharmacology, Wayne State University School of Medicine, 540 E. Canfield Ave., Detroit, MI 48201, United States. [srterlecky@med.wayne.edu](mailto:srterlecky@med.wayne.edu)

Telephone: +1-313-5773557 Fax: +1-313-5776739

Received: July 27, 2011 Revised: May 10, 2012

Accepted: May 17, 2012

Published online: May 26, 2012

### Abstract

Peroxisomes are intracellular organelles mediating a wide variety of biosynthetic and biodegradative reactions. Included among these are the metabolism of hydrogen peroxide and other reactive species, molecules whose levels help define the oxidative state of cells. Loss of oxidative equilibrium in cells of tissues and organs potentiates inflammatory responses which can ultimately trigger human disease. The goal of this article is to review evidence for connections between peroxisome function, oxidative stress, and inflammation in the context of human health and degenerative disease. Dysregulated points in this nexus are identified and potential remedial approaches are presented.

© 2012 Baishideng. All rights reserved.

**Key words:** Peroxisomes; Oxidative stress; Inflammation

**Peer reviewers:** Antonio Brunetti, MD, PhD, Professor, Cattedra di Endocrinologia, Università di Catanzaro "Magna Græcia", 88100 Catanzaro, Italy; Manuel Vazquez-Carrera, Dr., University of Barcelona, Unitat de Farmacologia. Facultat de Farmacia. Diagonal 643, E-08028 Barcelona, Spain

Terlecky SR, Terlecky LJ, Giordano CR. Peroxisomes, oxidative stress, and inflammation. *World J Biol Chem* 2012; 3(5): 93-97  
Available from: URL: <http://www.wjgnet.com/1949-8454/full/v3/i5/93.htm> DOI: <http://dx.doi.org/10.4331/wjbc.v3.i5.93>

### INTRODUCTION


Peroxisomes are essential organelles of human cells. In this article, we review peroxisome biology; summarizing how the organelle is formed, how it functions, and what happens when these processes are compromised. In addition, we describe an emergent link between the organelle and cellular aging pathways. In the latter analysis, we connect peroxisome function with the generation and destruction of specific inflammatory mediators and speculate on the organelle's involvement in initiating and progressing human disease.

### PEROXISOME FUNCTION

#### Degradation

Peroxisomes synthesize and degrade a wide variety of cellular compounds<sup>[1]</sup>. Through  $\alpha$ - and  $\beta$ -oxidations, specific long-chain, very-long-chain, and 3-methyl-branched-chain fatty acids are degraded. These processes may occur entirely within the organelle or may involve participation of other organelles - e.g., mitochondria. The notion that peroxisomes shuttle metabolites for continued processing and/or anaplerotic metabolism is part of an emergent theme for the organelle; specifically, that it is integrated into a variously interacting endomembrane system responsible for a number of critical cellular processes<sup>[2]</sup>.

The peroxisome's handling of hydrogen peroxide, a reactive oxygen species produced by oxidative reactions occurring within the organelle, also bears on this point. Under most conditions, hydrogen peroxide is produced and immediately processed by the organelle's resident



**Figure 1** Emergent connections between peroxisomes and cellular metabolism.

marker enzyme, catalase. However, conditions exist in which the balance of hydrogen peroxide production is upset, and the potentially toxic metabolite accumulates<sup>[3-7]</sup>. As discussed further below, such phenomena set cells on a pro-aging program with potentially important health ramifications<sup>[2]</sup>.

Other catabolic functions carried out by peroxisomes include degradation of polyamines, glyoxylate, certain amino acids, and several xenobiotics<sup>[1]</sup>. In addition, the organelle breaks down the arachidonic acid derivatives known as eicosanoids. Eicosanoids are critically important signaling molecules which exert tremendous control over inflammatory reactions<sup>[8]</sup>. Among the arachidonic acid derivatives under consideration here are prostaglandins, thromboxanes, leukotrienes, and prostacyclins. These compounds elicit broad ranging inflammatory reactions depending on concentration and location.

Included among the activities engendered by these molecules are modulating vasoconstriction/vasodilation and smooth muscle contraction/relaxation, controlling platelet aggregation, regulating hormone release/metabolism, and initiating pyrogenic (i.e., febrile) responses<sup>[8]</sup>. And these examples only partially represent the broad physiological effects elicited by eicosanoids. The important point is that through their ability to be metabolized by peroxisomes - organelle function is linked to the inflammatory response.

Inflammation could not be a more popular topic in current medical research. There is a sense in the clinical community that inflammation plays a major role in aging and in chronic diseases. Indeed, the term “inflammaging” has been coined and is in use. Targeting inflammation is popularly seen as a major strategy to combat these processes. Specific pathways involving the presence of

reactive oxygen species and chronic activation of inflammatory pathways are examined further below.

### Synthesis


Peroxisomes contain enzymes which contribute to the synthesis of critical cellular constituents including bile acids, ether phospholipids, and docosahexaenoic acids, among others<sup>[1]</sup>. Bile acids, derived from cholesterol, are important molecules involved in digestion through their ability to emulsify fats. Ether phospholipids, including plasmalogens, represent a vital class of membrane protective molecules, found throughout cells of the body. Myelin, the insulating layer of nerve sheaths, contains plasmalogens; absence of the ether phospholipid is associated with progressive neurological impairment<sup>[9]</sup>. Docosahexaenoic acids, peroxisomally produced omega-3 fatty acids, are the pivotal precursors of resolvins (“resolution-phase interaction products”), maresins (“macrophage mediator in resolving inflammation”), and protectins (formerly called “neuroprotectins”)<sup>[10-12]</sup>. These molecules possess potent anti-inflammatory, inflammatory resolving, and immunoregulatory activities. Importantly, conversion of docosahexaenoic acids to these biologically active mediators is accelerated by non-steroidal anti-inflammatory drugs, including aspirin, which inhibits the cyclooxygenase-2 enzyme<sup>[8]</sup>.

## PEROXISOME FORMATION

### Biogenesis

From a functional perspective, the peroxisome is clearly a major player in cellular metabolism and a key component of organismal physiology. As to how it acquires these capacities, the answer lies in a magnificently choreographed series of biochemical processes which bring about its biogenesis<sup>[13]</sup>.

Defining the origins of the peroxisome membrane has taken some time - many years in fact. Growth and division of existing organelles gained considerable early support until evidence was obtained that the endoplasmic reticulum was also providing membrane<sup>[14]</sup>. The current consensus is that both processes contribute to peroxisome membrane growth and proliferation<sup>[13]</sup>. Once assembled, the peroxisome membrane acquires additional membrane proteins including those constituting the import machinery. Although still not described in complete detail, this apparatus is known to consist of the following components: soluble receptors which recognize peroxisomal targeting signals on nascent proteins/enzymes; docking proteins which serve to concentrate and direct the receptor-ligand complex at the organelle membrane; and several molecules involved in facilitating the translocation process and recycling essential components for additional rounds of import<sup>[13]</sup>. Mechanisms are in place to recycle unneeded, damaged, or aged import factors, as well as to degrade the entire organelle when appropriate.



**Figure 2** Inflammation, oxidative stress, and aging as driving forces of human disease. Listed here are human diseases in which the emergent connections displayed in Figure 1, most importantly oxidative stress and inflammation, are thought to trigger a pro-aging program in cells and initiate or progress pathology.

### Redox balance

Many of the enzymes imported by peroxisomes oxidize substrates and produce hydrogen peroxide as a metabolic by-product. This hydrogen peroxide is normally processed to water and oxygen by catalase or other organellar peroxidases, thus maintaining oxidative balance. In recent years, several circumstances have been described in which the balance is upset and peroxisomes begin to produce excess hydrogen peroxide and related downstream reactive oxygen species. These include certain disease states in which catalase is either not produced or is unstable<sup>[15-17]</sup>, as well as situations in which the enzyme is inactivated<sup>[7]</sup> or mislocalized<sup>[3,18]</sup>. Certain xenobiotics/environmental toxins appear to be able to inhibit activity of the enzyme, and aging cells are progressively less able to correctly compartmentalize the critical antioxidant enzyme.

Under conditions in which peroxisomal reactive oxygen species amass, dramatic effects on cells are seen. For example, cellular proteins, lipids, and DNA are oxidatively damaged, organelle function is compromised and metabolism is slowed<sup>[3,4,7,18]</sup>.

### Genetic disease

Peroxisomes fail to form or are deficient in one or more of their constituent enzymes in a series of devastating genetic diseases described in ever greater detail over the past 30 years or so<sup>[19,20]</sup>. The severity of the clinical manifestations reflects the extent of the organelle's impaired function. Many affected children die within the first decade of life with deficits manifest in nearly all organ systems. To

date, treatment approaches have largely been limited to palliative care. Advances in gene and/or protein therapies promise to improve clinical outcomes.

### Oxidative stress, inflammation, and degenerative disease

Oxidative stress and inflammation are inextricably tied processes. Chronic inflammation is associated with elevated reactive oxygen species levels; anti-inflammatory cascades are linked to diminished reactive oxygen species concentrations. And the converse is true - elevated oxidative stress triggers inflammation, whereas redox balance inhibits the cellular response. Thus, oxidative stress and inflammation may be seen as both causes and consequences of cellular pathology. We suggest here that through the peroxisome's role in cellular redox balance, as well as its ability to synthesize various anti-inflammatory molecules and degrade pro-inflammatory mediators, the organelle is part of a critical network controlling cell function and organismal well-being (Figure 1). What is surprising is that these vital roles for the organelle have been unappreciated for so long.

We have previously argued that peroxisomes function as important communication centers - integrating signals from various sources to alter their own metabolism as well as that of other organelles, and to initiate or inhibit cellular aging programs<sup>[2]</sup>. A major redox-based interplay exists between peroxisomes and mitochondria, a relationship that warrants additional analysis. Several reports indicate that altering peroxisomal redox balance triggers

oxidative stress in mitochondria - resulting in reactive oxygen species production, diminished membrane potential, and compromised organelle function<sup>[7,21]</sup>. Obviously, the cellular consequences of diminished mitochondrial function are profound. However, restoring peroxisomal redox balance - for example by supplementing (peroxisomal) catalase, renews mitochondria<sup>[18]</sup>. Mitochondria repolarize and aging cells delay appearance of senescence markers. Increasing oxidative stress in peroxisomes is “progeric” on cells; eliminating the stress revives them.

This approach of targeted antioxidant prophylaxis has also been successful in disease models. For example, in a human cell model for psoriasis, catalase supplementation reduces expression of the inflammatory cytokine, tumor necrosis factor  $\alpha$ , that is thought to be a major initiator of the chronic inflammation seen in psoriatic tissue<sup>[22]</sup>. Similarly, in *in vitro*<sup>[23]</sup> and *in vivo* (Terlecky SR - unpublished) models of ischemia-reperfusion (heart attack), damage to cardiomyocytes and cardiac tissue is dramatically inhibited. In a rat cell model of Alzheimer’s disease,  $\beta$ -amyloid peptide-induced neuronal toxicity is significantly reduced (Terlecky SR - unpublished). Enhancing peroxisomal catalase also reduces inflammatory cytokine production in appropriately challenged human fibroblasts (Terlecky SR - unpublished). The evidence is mounting - peroxisome redox balance is a major determinant of cell stress and the presence or absence of cell pathology. Perhaps it is not surprising then that epidemiological studies suggest a very strong link exists between diminishing cellular catalase levels and the onset of degenerative disease<sup>[24]</sup>.

## CONCLUSION

The treatment of human degenerative disease requires, in our view, a distance from the reductionist and extremely focused approaches long applied by the scientific and medical communities. Rather, we suggest a broader attack, targeting oxidative stress, chronic inflammation, and the resultant pro-aging programs initiated in cells and tissues (Figure 2). There are many ways to approach this - the direction discussed in this article focuses on the peroxisome. The organelle plays a key role in controlling inflammation and maintaining oxidative balance in cells. By targeting peroxisomes - perhaps a number of devastating diseases could be more effectively treated or prevented. We suggest enhancing peroxisome function and maintaining the organelle’s redox balance by all means possible. Mitochondrial integrity/activity will be maintained or enhanced, oxidative stress will be reduced, inflammation will be held in check, and cellular pathology will be all but eliminated. Optimistic dreams? Perhaps. But as is often said in science, “That’s why you do the experiment”.

## ACKNOWLEDGMENTS

We thank Kendra Krentz for careful reading of the manuscript.

## REFERENCES

- 1 **Wanders RJ**, Waterham HR. Biochemistry of mammalian peroxisomes revisited. *Annu Rev Biochem* 2006; **75**: 295-332
- 2 **Titorenko VI**, Terlecky SR. Peroxisome metabolism and cellular aging. *Traffic* 2011; **12**: 252-259
- 3 **Legakis JE**, Koepke JI, Jedeszko C, Barlaskar F, Terlecky LJ, Edwards HJ, Walton PA, Terlecky SR. Peroxisome senescence in human fibroblasts. *Mol Biol Cell* 2002; **13**: 4243-4255
- 4 **Wood CS**, Koepke JI, Teng H, Boucher KK, Katz S, Chang P, Terlecky LJ, Papanayotou I, Walton PA, Terlecky SR. Hypocatalasemic fibroblasts accumulate hydrogen peroxide and display age-associated pathologies. *Traffic* 2006; **7**: 97-107
- 5 **Kawada Y**, Khan M, Sharma AK, Ratnayake DB, Dobashi K, Asayama K, Moser HW, Contreras MA, Singh I. Inhibition of peroxisomal functions due to oxidative imbalance induced by mistargeting of catalase to cytoplasm is restored by vitamin E treatment in skin fibroblasts from Zellweger syndrome-like patients. *Mol Genet Metab* 2004; **83**: 297-305
- 6 **Sheikh FG**, Pahan K, Khan M, Barbosa E, Singh I. Abnormality in catalase import into peroxisomes leads to severe neurological disorder. *Proc Natl Acad Sci USA* 1998; **95**: 2961-2966
- 7 **Koepke JI**, Wood CS, Terlecky LJ, Walton PA, Terlecky SR. Progeric effects of catalase inactivation in human cells. *Toxicol Appl Pharmacol* 2008; **232**: 99-108
- 8 **Smyth EM**, FitzGerald GA. The Eicosanoids: Prostaglandins, Thromboxanes, Leukotrienes, & Related Compounds. 10th ed. In: Katzung BG, editor. Basic and Clinical Pharmacology. New York: McGraw-Hill Companies, 2007: 293-308
- 9 **Kassmann CM**, Lappe-Siefke C, Baes M, Brügger B, Mildner A, Werner HB, Natt O, Michaelis T, Prinz M, Frahm J, Nave KA. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. *Nat Genet* 2007; **39**: 969-976
- 10 **Ariel A**, Serhan CN. Resolvins and protectins in the termination program of acute inflammation. *Trends Immunol* 2007; **28**: 176-183
- 11 **Serhan CN**, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. *J Exp Med* 2009; **206**: 15-23
- 12 **Das UN**. Lipoxins, resolvins, protectins, maresins, and nitrolipids: connecting lipids, inflammation, and cardiovascular disease risk. *Curr Cardio Risk Rep* 2010; **4**: 24-31
- 13 **Ma C**, Agrawal G, Subramani S. Peroxisome assembly: matrix and membrane protein biogenesis. *J Cell Biol* 2011; **193**: 7-16
- 14 **Geuze HJ**, Murk JL, Stroobants AK, Griffith JM, Kleijmeer MJ, Koster AJ, Verkleij AJ, Distel B, Tabak HF. Involvement of the endoplasmic reticulum in peroxisome formation. *Mol Biol Cell* 2003; **14**: 2900-2907
- 15 **Eaton JW**, Ma M. Acatlasemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995: 2371-2383
- 16 **Wen JK**, Osumi T, Hashimoto T, Ogata M. Diminished synthesis of catalase due to the decrease in catalase mRNA in Japanese-type acatalasemia. *Physiol Chem Phys Med NMR* 1988; **20**: 171-176
- 17 **Crawford DR**, Mirault ME, Moret R, Zbinden I, Cerutti PA. Molecular defect in human acatalasia fibroblasts. *Biochem Biophys Res Commun* 1988; **153**: 59-66
- 18 **Koepke JI**, Nakrieko KA, Wood CS, Boucher KK, Terlecky LJ, Walton PA, Terlecky SR. Restoration of peroxisomal catalase import in a model of human cellular aging. *Traffic* 2007; **8**: 1590-1600
- 19 **Steinberg SJ**, Dodt G, Raymond GV, Braverman NE, Moser

- AB, Moser HW. Peroxisome biogenesis disorders. *Biochim Biophys Acta* 2006; **1763**: 1733-1748
- 20 **Wanders RJ**, Waterham HR. Peroxisomal disorders: the single peroxisomal enzyme deficiencies. *Biochim Biophys Acta* 2006; **1763**: 1707-1720
- 21 **Ivashchenko O**, Van Veldhoven PP, Brees C, Ho YS, Terlecky SR, Fransen M. Intraperoxisomal redox balance in mammalian cells: oxidative stress and interorganellar cross-talk. *Mol Biol Cell* 2011; **22**: 1440-1451
- 22 **Young CN**, Koepke JI, Terlecky LJ, Borkin MS, Boyd Savoy L, Terlecky SR. Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. *J Invest Dermatol* 2008; **128**: 2606-2614
- 23 **Undyala V**, Terlecky SR, Vander Heide RS. Targeted intracellular catalase delivery protects neonatal rat myocytes from hypoxia-reoxygenation and ischemia-reperfusion injury. *Cardiovasc Pathol* 2011; **20**: 272-280
- 24 **Góth L**, Eaton JW. Hereditary catalase deficiencies and increased risk of diabetes. *Lancet* 2000; **356**: 1820-1821

S- Editor Cheng JX L- Editor A E- Editor Zheng XM

## Septin 8 is an interaction partner and *in vitro* substrate of MK5

Alexey Shiryayev, Sergiy Kostenko, Gianina Dumitriu, Ugo Moens

Alexey Shiryayev, Sergiy Kostenko, Gianina Dumitriu, Ugo Moens, Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, N-9037 Tromsø, Norway

**Author contributions:** Moens U conceived the study; Shiryayev A, Kostenko S, Dumitriu G and Moens U designed and interpreted the experiments; Shiryayev A, Kostenko S and Dumitriu G performed the experiments; Shiryayev A and Moens U wrote the paper. **Supported by** Grants from the Norwegian Cancer Society (A5313) to Shiryayev A

**Correspondence to:** Dr. Ugo Moens, Professor, Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, N-9037 Tromsø, Norway. [ugo.moens@uit.no](mailto:ugo.moens@uit.no)  
Telephone: +47-77644622 Fax: +47-77645350  
Received: January 31, 2012 Revised: March 9, 2012  
Accepted: March 16, 2012  
Published online: May 26, 2012

### Abstract

**AIM:** To identify novel substrates for the mitogen-activated protein kinase-activated protein kinase 5 (MK5).

**METHODS:** Yeast two-hybrid screening with MK5 as bait was used to identify novel possible interaction partners. The binding of putative partner was further examined by glutathione S-transferase (GST) pull-down, co-immunoprecipitation and fluorescence resonance energy transfer (FRET) analysis. *In vitro* kinase and peptide array assays were used to map MK5 phospho-acceptor sites on the new partner. Confocal microscopy was performed to study the subcellular localization of MK5 and its partners.

**RESULTS:** Septin 8 was identified as a novel interaction partner for MK5 by yeast two-hybrid screening. This interaction was confirmed by GST pull-down, co-immunoprecipitation and FRET analysis. Septin 5, which can form a complex with septin 8, did not interact with MK5. Serine residues 242 and 271 on septin 8 were identified as *in vitro* MK5 phosphorylation sites. MK5 and septin 8 co-localized in the perinuclear area and in

cell protrusions. Moreover, both proteins co-localized with vesicle marker synaptophysin.

**CONCLUSION:** Septin 8 is a bona fide interaction partner and *in vitro* substrate for MK5. This interaction may be implicated in vesicle trafficking.

© 2012 Baishideng. All rights reserved.

**Key words:** Mitogen-activated protein kinase-activated protein kinase-5; Fluorescence resonance energy transfer; Septin; Phosphorylation; Synaptophysin

**Peer reviewers:** Hong-Gang Wang, PhD, Professor, Lois High Berstler Professor of Pharmacology, Penn State College of Medicine, Penn State Hershey Cancer Institute, CH74, 500 University Drive, PO Box 850, Hershey, PA 17033-0850, United States; Wayne Grant Carter, PhD, School of Biomedical Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, United Kingdom

Shiryayev A, Kostenko S, Dumitriu G, Moens U. Septin 8 is an interaction partner and *in vitro* substrate of MK5. *World J Biol Chem* 2012; 3(5): 98-109 Available from: URL: <http://www.wjgnet.com/1949-8454/full/v3/i5/98.htm> DOI: <http://dx.doi.org/10.4331/wjbc.v3.i5.98>

### INTRODUCTION

The group of mitogen-activated protein kinases (MAPKs) participates in control of several vital processes, including metabolism, transcription, apoptosis, cell cycle progression, differentiation, cytoskeletal rearrangement and cell movement. MAPK-activated protein kinase 5 (MK5), also designated PRAK, belongs to the group of kinases downstream of MAPK, originally identified as *in vitro* p38 MAPK substrate<sup>[1,2]</sup>. Biological functions of MK5 are poorly understood despite the high similarity in structure with other widely studied members of the subgroup<sup>[3]</sup>. Recent studies have highlighted the importance of MK5

in ras-induced senescence, antiproliferation, tumor suppression, anxiety-related behavior, energy-depletion-induced suppression of mammalian target of rapamycin C1, rearrangements of the cytoskeleton, endothelial cell migration, and tumor angiogenesis<sup>[4-9]</sup>. Several *bona fide* substrates have been identified, including extracellular signal-regulated kinase (ERK)3, ERK4, 14-3-3 $\epsilon$ , p53, Ras homolog enriched in brain (Rheb) and heat shock protein (Hsp)27<sup>[6,8,10-15]</sup>. The role of MK5 in actin architecture involves its link with 14-3-3 $\epsilon$  and Hsp27<sup>[14,15]</sup>, while MK5-mediated phosphorylation of p53 at Ser-37 results in increased transcription of p21<sup>Cip1</sup>, and inhibition of cell proliferation<sup>[6,16]</sup>. The biological relevance of MK5-ERK3 and MK5-ERK4 interactions remains unknown.

Septins belong to a group of small GTPases that were originally described in the budding yeast *Saccharomyces cerevisiae* as a group of cell division cycle regulatory genes. Proteins were isolated in yeast through the analysis of temperature-sensitive mutants showing impaired cytokinesis and budding<sup>[17]</sup>. Their role in formation of the septum between mother and daughter yeast cells is the background for the given name septins<sup>[17,18]</sup>. Septins are highly conserved and have been identified in most cell types of multicellular organisms<sup>[19]</sup>. Fourteen septin genes (*SEPT1-SEPT14*) have been characterized to date in humans<sup>[20]</sup>. Septin genes undergo alternative splicing and produce multiple protein products that are expressed at different ratios in different tissues<sup>[20]</sup>. These GTP-binding proteins are involved in diverse processes such as cytokinesis, membrane remodeling and compartmentalization, cytoskeleton rearrangement, vesicle trafficking, and apoptosis<sup>[18,20,21]</sup>. Knockout mice have been generated for *SEPT3*, 4, 5, 6, 7 and 9 genes<sup>[22]</sup>. *SEPT7*<sup>-/-</sup> and *SEPT9*<sup>-/-</sup> mice were embryonic lethal, while *SEPT3*<sup>-/-</sup> and *SEPT6*<sup>-/-</sup> mice had no obvious phenotype<sup>[23,24]</sup>. *SEPT4*<sup>-/-</sup> mice had defects in behavior and reproduction, while *SEPT5*<sup>-/-</sup> animals had elevated platelet hypersensitivity<sup>[25-27]</sup>. Septins have been reported to be perturbed in various human diseases, including neurological disorders, infection, and neoplasia<sup>[28]</sup>.

SEPT8 was first identified as an interaction partner for SEPT5 by yeast two-hybrid screening<sup>[29]</sup>, and is an alternatively spliced septin with 14 known transcripts and 10 different isoforms that are expressed in a variety of human tissues<sup>[20]</sup>. SEPT-SEPT interaction studies using yeast two- and three-hybrid assays revealed heterodimeric SEPT2:SEPT8, SEPT3:SEPT8, SEPT4:SEPT8, SEPT7:SEPT8 and SEPT9:SEPT8 complexes and heterotrimeric SEPT2:SEPT8:SEPT7, SEPT4:SEPT8:SEPT7, SEPT5:SEPT8:SEPT7, SEPT2:SEPT8:SEPT9, SEPT4:SEPT8:SEPT9, SEPT5:SEPT8:SEPT9 complexes<sup>[30]</sup>. SEPT8 together with SEPT4 and SEPT5 have been designated platelet septins due to high expression and interaction in these cells. Moreover all three septins are highly expressed in brain and heart tissues as well as in prostate, testis and ovary<sup>[31]</sup>. In platelets, they have marked preference for areas surrounding  $\alpha$ -granules. Activation of platelets leads to translocation of SEPT4 and SEPT8 to the platelet surface<sup>[32]</sup>. SEPT5 is involved in exocytosis (serotonin release) in platelets and may regulate synaptic vesicle

dynamics<sup>[25,33-35]</sup>. SEPT8 is expressed in rat brain and expression is developmentally regulated<sup>[36]</sup>. Besides septin proteins, other proteins have been shown to interact with SEPT8. Vesicle-associated membrane protein (VAMP)2 and syntaxin1A have been identified as binding partners for SEPT8. Furthermore, SEPT8 in rat brain disrupts the binding of VAMP2 to synaptophysin. These results suggest a possible involvement of SEPT8 in the regulation of soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex formation and subsequent exocytosis<sup>[36]</sup>, but experimental proof is lacking and the biological role of SEPT8 remains unknown.

To increase the understanding of biological functions of MK5, we used the yeast two-hybrid system and identified SEPT8 as a new interaction partner. SEPT8 appears to be phosphorylated by MK5 *in vitro*. These two proteins showed co-localization in the perinuclear area or protrusions of the cells as well as co-localization with synaptophysin in a neuroblastoma cell line. These results support previous assumptions on the role of SEPT8 in exocytosis and may indicate a possible involvement of MK5 in regulated secretion through phosphorylation of SEPT8.

## MATERIALS AND METHODS

### Yeast two-hybrid screening

Yeast two-hybrid screening of MK5 was performed in yeast PBN204 strain containing three reporters (*URA3*, *lacZ*, and *ADE2*) that are under the control of different *GAL* promoters. Yeast transformants of the MK5 bait and human brain cDNA AD library were spread on selection medium (SD-leucine, tryptophan, uracil; SD-LWU) that supports growth of yeast with bait and prey plasmids yielding proteins interacting with each other.

### Antibodies

The anti-PRAK (A7) and anti-SEPT8 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, United States). Anti-synaptophysin fluorescein isothiocyanate (FITC) conjugate (SY38) antibodies were purchased from Progen Biotechnik GmbH (Heidelberg, Germany). The alkaline-phosphatase-conjugated secondary antibodies sheep anti-mouse IgG and anti-rabbit IgG were from Sigma Aldrich (St. Louis, MO, United States).

### Plasmid construction and mutagenesis

The plasmid pRK5-flag-Sept8 was a kind gift from Dr. Koh-Ichi Nagata and Dr. Masaki Inagaki (Aichi Cancer Center Research Institute, Nagoya, Japan)<sup>[37]</sup>. pGEX-Sept8 and AsRed-Sept8 plasmids were generated by digesting pRK5-flag-Sept8 with *EcoRI* and *XbaI* or *BspEI* and *XbaI*, respectively, and ligation into corresponding vectors, namely pGEX-4T-1 (GE Healthcare, Oslo, Norway) and AsRed-C1 (BD Biosciences, Trondheim, Norway). All plasmids were verified by sequencing. The MK5 expression plasmid has been previously described<sup>[38]</sup>. The oligonucleotides 5'-GCAGTTCGACATGGCGGC-CACCGACCTGGA-3' and 5'-TATGCGGCCGCT-TAATTCCTTCTTGTCTCCTTG-3' were used to amplify

SEPT8-fragment from pRK5-Flag-Sept8. Then, the fragment of SEPT8 was cut with *SmaI/NotI* and ligated into the corresponding sites of pENTR1A (Invitrogen, Dynal AS, Oslo, Norway). The pEGFP-MK5 was digested with *SmaI/EcoRI*, and the fragment ligated into the corresponding sites of pBluescript SK plus. The resulting pBluescript-MK5 construct was then digested with *EcoRI/NotI*, and the fragment ligated into the corresponding sites of pENTR2B (Invitrogen). The pcDNA-CREB (cAMP response element-binding protein) plasmid was digested with *KpnI/NotI*, and the fragment ligated into the corresponding sites of pENTR3C (Invitrogen). The resulting pENTR-SEPT8, pENTR-MK5 and pENTR-CREB clones were further recombined with Gateway destination vectors pDest-EYFP and pDest-ECFP (a gift from Dr. Terje Johansen, University of Tromsø, Norway) generating EYFP-SEPT8, ECFP-SEPT8, EYFP-MK5, ECFP-MK5, EYFP-CREB and ECFP-CREB.

### Glutathione S-transferase-fusion protein purification

Glutathione S-transferase (GST) fusion proteins were purified from *Escherichia coli* (*E. coli*) BL21 extracts using glutathione-agarose beads as previously described<sup>[38]</sup>, and the GST moiety was removed from the GST beads by use of thrombin according to the instructions of the manufacturer.

### In vitro kinase assays

Peptide arrays were synthesized on cellulose paper by using MultiPep automated multiple peptide synthesizer (INTAVIS Bioanalytical Instruments, Köln, Germany). Successive 20-mer peptides spanning the complete SEPT8 protein were synthesized. Each consecutive peptide had a three-amino-acid shift compared to the previous peptide. For phosphorylation, membranes were briefly wet in ethanol prior to incubation in phosphorylation buffer [20 mmol/L HEPES, pH 7.4, 100 mmol/L NaCl, 5 mmol/L MgCl<sub>2</sub>, 1 mmol/L dithiothreitol (DTT), and 0.2 mg/mL bovine serum albumin (BSA)] for 1 h at room temperature. Thereafter, the array was incubated at 4 °C overnight in blocking buffer (phosphorylation buffer containing 1 mg/mL BSA and 100 μmol/L ATP). Phosphorylation was initiated by incubating the membrane in the presence of activated MK5 (Millipore Upstate, Billerica, MA, United States) in 20 mL phosphorylation buffer containing 50 μmol/L ATP and 0.37 MBq of [<sup>32</sup>P] ATP for 30 min at 30 °C with agitation. The membrane was washed extensively in 1 mol/L NaCl followed by washes in 5% H<sub>3</sub>PO<sub>4</sub> and dried down<sup>[39]</sup>. The phosphorylated membrane was then visualized by the FUJIFILM BioImaging Analyser (type BAS-5000). *In vitro* phosphorylation of SEPT8 by activated MK5 was performed in 25 mmol/L Tris-HCl, pH 7.5, 10 mmol/L MgCl<sub>2</sub>, 0.05 mg/mL BSA, 2.5 mmol/L DTT, 0.15 mmol/L cold ATP, and 0.3 μL [<sup>32</sup>P] ATP (3000 Ci/mmol; GE Healthcare) in a total volume of 40 μL at 30 °C for 1 h. The reaction was stopped in 4 × lithium dodecyl sulfate (LDS) Sample buffer, and proteins were denatured at 70 °C for 10 min. The phosphorylation was analyzed on NuPAGE 4%-12% BisTris SDS-PAGE (Invitrogen) for 50 min at 200 V and then subjected to autoradiography.

### Cell culture and transfections

The human neuroblastoma cell line SK-N-DZ (CRL-2194) was from ATCC (LGC Promochem, Middlesex, United Kingdom), while PC12 cells were purchased from the European Collection of Cell Culture (ECACC; Wiltshire, United Kingdom). The cells were maintained in RPMI 1640, supplemented with 10% horse serum (Gibco) and 5% fetal bovine serum, 2 mmol/L L-glutamine, penicillin (110 U/mL) and streptomycin (100 μg/mL). Cells were transfected using the Nucleofection kit (Amaxa) according to the manufacturer's instructions. HEK293 cells (ATCC CRL-1573) and HeLa cells (ATCC CCL-2) were purchased from the American Type Culture Collection (LGC Standards, Borås, Sweden) and maintained in Eagle's minimum essential medium supplemented with 10% fetal calf serum (Invitrogen Life Technologies, Carlsbad, CA, United States), 2 mmol/L L-glutamine, (110 U/mL) and streptomycin (100 μg/mL). HeLa cells also received 1 × nonessential amino acids (Invitrogen). HeLa cells were transfected with Lipofectamine 2000 (Invitrogen).

### Co-immunoprecipitation

HEK293 cell extracts were harvested and lysed in buffer containing 20 mmol/L Tris-HCl, pH 7.5, 1% Triton X-100, 5 mmol/L sodium pyrophosphate, 50 mmol/L sodium fluoride, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L sodium orthovanadate, 0.27 mol/L sucrose, 10 mmol/L β-glycerophosphate, and complete protease inhibitor cocktail (Roche Applied Sciences, Oslo, Norway). Lysates were cleared by centrifugation at 4 °C for 10 min at 15 000 g. Lysates were incubated with the appropriate antibody for at least 1 h at 4 °C, before addition of 60 μL slurry [i.e., 30 μL protein G-agarose (GE Healthcare) equilibrated with 30 μL lysis buffer] and incubated for an additional 1 h. The immunoprecipitates were then washed three times in lysis buffer and twice in 50 mmol/L Tris-HCl, pH 8.0. Twenty microliters of 2 × LDS sample buffer were added to the beads before denaturation at 70 °C for 10 min. The immunoprecipitates were analyzed on western blotting.

### Fluorescent microscopy and fluorescence resonance energy transfer

Cells with ectopically expressed proteins fused with green fluorescent protein or red fluorescent proteins were analyzed directly using confocal laser scanning microscope (LSM 510 META; Zeiss, Oslo, Norway). For fluorescence resonance energy transfer (FRET) analysis, HeLa cells were cotransfected with ECFP-MK5 and EYFP-SEPT8 or EYFP-CREB using TransIT-LT1 transfection reagent (Mirus Bio LLC, Madison, WI, United States). Then, 24 h after transfection, the cells were fixed with 4% formaldehyde. FRET analysis was carried out with a Leica TCS SP5 confocal microscope with a × 63, 1.2 W objective. Cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP) were excited with separate laser channels of 458 and 514 nm, respectively. Emission fluorescence intensity data was obtained at 465-500 nm (CFP) and 525-600 nm (YFP). CFP and YFP emission

signals were captured before and after 50% photobleaching YFP. FRET is indicated as the relative increase in CFP emission following YFP photobleaching. The imaging system was controlled by the Leica Application Suite Advanced Fluorescence software (<http://www.leicamicrosystems.com>).

### Western blotting

For detection of coimmunoprecipitates and SEPT8, samples were analyzed by SDS-PAGE on NuPAGE 4%-12% BisTris SDS-PAGE gels from Invitrogen according to the manufacturer's protocol and blotted onto a 0.45- $\mu$ m polyvinylidene difluoride membrane (Millipore). Immunoblotting was performed by first blocking the membrane with phosphate buffered solution (PBS)-T [PBS with 0.1% Tween 20 (Sigma) containing 10% (w/v) dried skimmed milk for 1 h and probed either by anti-PRAK or anti-SEPT8]. After three washes, the membrane was incubated with the appropriate secondary antibody for 1 h. Visualization of proteins was achieved by using CDP Star substrate (Tropix, Bedford, MA, United States) and Lumi-Imager F1 from Roche Applied Sciences. MagicMark™ western standard was from Invitrogen Life Technologies.

### GST pull down

Cell lysate was precleared with 25 mg GST and 50 mL 50% slurry of glutathione-agarose beads for 2 h at 4 °C. An input control was taken, and the cell lysate was divided into two tubes and 10 mg GST or GST-SEPT8 were added. The GST proteins were recovered after addition of glutathione beads and washed extensively in PBS-T. The proteins were eluted from the beads by addition of 20 mL loading buffer (LDS-buffer with 100 mmol/L DTT) followed by 10 min incubation at 70 °C. The GST proteins were subsequently subjected to immunoblot analysis.

### Densitometry

Densitometry was performed using a BioRad Model GS-700 Imaging Densitometer (Oslo, Norway) and the Multi-Analyst version 1.1 Software.

## RESULTS

### Screening of proteins that interact with MK5

To elaborate the biological functions of MK5, we decided to identify novel substrates for MK5. A yeast two-hybrid screen with MK5 as bait and a brain cDNA library was designed. After selecting yeast colonies on uracil-deficient medium, the activity of  $\beta$ -galactosidase was monitored. The URA<sup>+</sup> and lacZ<sup>+</sup> colonies were also tested for whether they could grow on adenosine-deficient medium. To maximize the specificity of the screening, protein-protein interaction was tested using three independent reporters with different types of GAL4-binding sites. This procedure eliminates interactions that result from nonspecific promoter activation. In order to confirm the interaction, the prey plasmids from 29 candidates that expressed at least two reporters were selected by *E. coli* transformation,

and then the candidate prey plasmids were reintroduced into yeast with MK5 bait plasmid or with a negative control plasmid expressing GAL4-binding domain but lacking the bait part. Twenty real positives were identified that encoded three different proteins. Among 20 real positives, 17 preys contained the same cDNA encoding SEPT8\_v2 (AF440762). Two other positive clones encoded the previously reported MK5 interaction partner ERK3<sup>[10,11]</sup>.

### SEPT8 binds to MK5 in vitro and in vivo


To verify the interaction observed in the yeast two-hybrid system, GST pull-down was performed. Lysates of HEK293 cells transfected with the expression plasmid for GFP-MK5 were incubated with glutathione-sepharose beads accompanied by either GST alone or GST-SEPT8. After immunoprecipitation, MK5 was detected by western blotting using anti-PRAK antibody. The results showed that MK5 could bind GST-SEPT8 (Figure 1A) but not GST alone.

To establish whether complexes of MK5 and SEPT8 existed within mammalian cells, HEK293 cells were co-transfected with MK5 and SEPT8 expression plasmids because these cells give high transfection efficiency. Reciprocal coimmunoprecipitation studies were conducted with anti-PRAK antibody followed by western blotting with anti-SEPT8 antibody, or immunoprecipitation with anti-SEPT8 antibody followed by western blotting with anti-PRAK antibody. Specific interaction was monitored between the two proteins (Figure 1B and C). The signal in the last lane in Figure 1C (lysate of cells expressing ectopically expressed SEPT8 but not MK5) was due to interaction of SEPT8 with endogenous MK5. No interactions were visualized in the control precipitation using vehicles. To detect interaction between endogenous MK5 and SEPT8, PC12 cells were used because both MK5 and SEPT8 are relatively highly expressed in neural cells<sup>[1,2,36]</sup>. MK5 could be detected when endogenous SEPT8 was immunoprecipitated (Figure 1D). Combined, our results clearly demonstrate that MK5 and SEPT8 specifically interact *in vitro* and *in vivo*. SEPT8 was originally identified as an interaction partner for SEPT5<sup>[29]</sup>, therefore, we tested whether MK5 and SEPT5 complexes were found in cells. Coimmunoprecipitation studies failed to detect MK5:SEPT5 complexes (results not shown).

We performed FRET analysis to monitor interaction between MK5 and SEPT8 in cells. HeLa cells were transfected with expression plasmids for MK5 and SEPT8. As a negative control, we included CREB because it does not interact with MK5<sup>[4]</sup>. After photobleaching, interaction between MK5 and SEPT8, but not MK5 and CREB, was observed as indicated by a relative increase in CFP emission following YFP photobleaching (Figure 2).

### MK5 phosphorylates SEPT8 in vitro

In previous studies, several septins have been shown to be phosphorylated *in vitro* and/or *in vivo*, including SEPT1, SEPT2, SEPT3 and SEPT5<sup>[40-44]</sup>. After describing the interaction between two proteins, we wanted to know whether MK5 possesses catalytic activity towards




**Figure 1 Mitogen-activated protein kinase-activated protein kinase 5 and SEPT8 interact *in vitro* and *in vivo*.** A: Glutathione S-transferase (GST) pull-down assay. GST-SEPT8 or GST alone purified from *Escherichia coli* and immobilized on glutathione-Sepharose beads were incubated for 60 min with lysate of HEK293 cells transfected with GFP-mitogen-activated protein kinase-activated protein kinase 5 (MK5). After washing the beads five times, bound proteins were eluted by boiling, subjected to SDS-PAGE, and immunoblotted with anti-PRAK (upper panel) or anti-SEPT8 (lower panel) antibody. Lane 1: Protein molecular mass marker (in kDa); lane 2: Cell lysate; lane 3: Cell lysate after pull down with GST; lane 4: Cell lysate after pull down with GST-SEPT8; B: Coimmunoprecipitation of FLAG-SEPT8 and hemagglutinin (HA)-MK5. HA-MK5- and/or FLAG-SEPT8-encoding plasmids were transiently expressed in HEK293 cells. Total cellular lysates (input; lanes 1-3) and SEPT8 immunoprecipitates (IP:  $\alpha$ -SEPT8; lanes 4-6) were probed with anti-PRAK (upper panel) and anti-SEPT8 (lower panel) antibody. Lane 1: Cell lysate of cells cotransfected with expression plasmids for HA-tagged MK5 and FLAG-tagged SEPT8; lane 2: Cell lysate of cells cotransfected with expression plasmids for HA-tagged MK5 and empty vector for SEPT8; lane 3: Cell lysate of cells cotransfected with expression plasmids for FLAG-tagged SEPT8 and empty vector for MK5; lane 4: Immunoprecipitated lysate of cells cotransfected with expression plasmids for HA-tagged MK5 and FLAG-tagged SEPT8; lane 5: Immunoprecipitated lysate of cells cotransfected with expression plasmids for HA-tagged MK5 and empty vector for SEPT8; lane 6: Immunoprecipitated lysate of cells cotransfected with expression plasmids for FLAG-tagged SEPT8 and empty vector for MK5; C: Coimmunoprecipitation of HA-MK5 and FLAG-SEPT8. HEK293 cells were transiently transfected with expression plasmids for HA-MK5 and/or FLAG-SEPT8. Total cellular lysates (input) and HA-MK5 immunoprecipitates (IP:  $\alpha$ -MK5) were probed with anti-SEPT8 (upper panel) and anti-PRAK (lower panel) antibody. Lanes 1-3: Lysates from transfected cells; lanes 4-6: Immunoprecipitation of cell lysates. See (B) for details; D: Coimmunoprecipitation of endogenous MK5 and SEPT8. Endogenous SEPT8 was immunoprecipitated from PC12 cells with anti-SEPT8 antibodies and the precipitate was analyzed for the presence of MK5 by anti-PRAK antibodies. Lane 1: Protein molecular mass marker (in kDa); lane 2: Lysate of PC12 cells (= input); lane 3: Immunoprecipitation with SEPT8 antibodies. The bottom panel shows control western blot with SEPT8 antibodies. IP: Immunoprecipitation; WB: Western blotting.

SEPT8. To test this, GST-SEPT8 fusion protein was purified from bacteria and the GST moiety was enzymatically cleaved. SEPT8 was then incubated with commercially available active MK5 in an *in vitro* kinase assay. Phosphoproteins were fractionated by SDS-PAGE on a 4%-20% acrylamide gradient gel and visualized by autoradiography. As shown in Figure 3A, SEPT8 was phosphorylated by MK5. As previously reported, MK5 autophosphorylation activity of MK5 was observed<sup>[38]</sup>. An additional band, corresponding to phosphorylated SEPT8 was detected. These results demonstrate that MK5 can phosphorylate of SEPT8 *in vitro*.


#### Identification of phosphorylation sites on SEPT8

To identify MK5 phosphoacceptor sites on SEPT8, we performed an *in vitro* kinase assay using peptide arrays. One separate peptide, YFTI<sup>237</sup>PT<sup>239</sup>GHS<sup>242</sup>LKS<sup>245</sup>LDLVT<sup>250</sup>MK K and two consecutive peptides IPIAKADT<sup>269</sup>IS<sup>271</sup>KS<sup>273</sup>ELHKFKI and IAKADT<sup>269</sup>IS<sup>271</sup>KS<sup>273</sup>ELHKFKIKIM

appeared phosphorylated (Figure 3B). Putative phosphoacceptor sites for the serine/threonine MK5 kinase are marked. We analyzed the SEPT8 sequence with NetPhos 2.0 (accessible on the internet: <http://www.cbs.dtu.dk/services/NetPhos/>). This software algorithm predicts the potential phosphorylation sites in proteins. According to the NetPhos description, scores close to 1 are the most likely to represent an actual phosphorylation site. Among all predicted sites, two serine residues in the sequences of peptides that were phosphorylated on peptide array had a high score, namely 0.994 for Ser-242 and 0.944 for Ser-271. We generated plasmids encoding GST-SEPT8<sup>242A</sup>, GST-SEPT8<sup>271A</sup> and GST-SEPT8<sup>242A/S271A</sup> in which these Ser residues were replaced by alanine and expressed these fusion proteins in bacteria. GST was enzymatically removed from the purified proteins and *in vitro* kinase assay with active MK5 was performed. Mutation of Ser-242 or Ser-271 into Ala reduced MK5-mediated phosphorylation of SEPT8, but the former substitution had less effect than



**Figure 2** Fluorescence resonance energy transfer analysis shows interaction between mitogen-activated protein kinase-activated protein kinase 5 and SEPT8. (A) HeLa cells were cotransfected with expression plasmids for heat shock protein (CFP)-tagged mitogen-activated protein kinase-activated protein kinase 5 (MK5) and yellow fluorescent protein (YFP)-tagged CREB or (B) with expression vectors for CFP-tagged MK5 and YFP-tagged SEPT8. Twenty-four hours after transfection, cells were fixed and fluorescence resonance energy transfer (FRET) analysis was carried out. CFP and YFP were excited with separate laser channels of 458 and 514 nm, respectively. Emission fluorescence intensity data were obtained at 465-500 nm (CFP) and 525-600 nm (YFP). CFP and YFP emission signals were captured before and after 50% photobleaching YFP. FRET is indicated as the relative increase in CFP emission following YFP photobleaching.



**Figure 3 Mitogen-activated protein kinase-activated protein kinase 5 phosphorylates septin 8 *in vitro*.** *A:* *In vitro* kinase assay on recombinant SEPT8. Glutathione S-transferase (GST)-SEPT8 fusion protein was purified from *Escherichia coli* and the GST moiety was removed by thrombin. SEPT8 was incubated with activated mitogen-activated protein kinase-activated protein kinase 5 (MK5) for 30 min at 30 °C in the presence of [ $\gamma$ -<sup>32</sup>P]ATP. Proteins were separated by SDS-PAGE and phosphorylation was visualized by autoradiography (upper panel). Loading control for MK5 (middle panel) and SEPT8 (lower panel) was performed by western blotting with anti-PRAK and anti-SEPT8 antibodies, respectively. Lane 1: Recombinant activated MK5; lane 2: Purified SEPT8 protein; lane 3: recombinant MK5 and purified SEPT8; *B:* SEPT8 peptide array was subjected to *in vitro* phosphorylation by activated MK5. Each spot represents a 20-mer peptide fragment of SEPT8. The peptide fragments constitute the complete SEPT8 protein. The sequential peptide has a 17-amino acid overlap with the previous peptide. Several spots with peptides were detected by autoradiography (lower panel). Ser-242 and Ser-271 with highest prediction score 0.994 and 0.944, respectively by Netphos software, were chosen as possible phosphorylation sites in the peptide sequences. The upper panel represents Ponceau staining of the peptide array membrane used. The sequences of the peptides representing the positive spots are shown; *C:* *In vitro* phosphorylation of wild-type SEPT8, and SEPT8 mutants carrying a single amino acid substitution (Ser-242 into Ala or Ser-271 into Ala, respectively) or the double amino acid substitution Ser-242 and Ser-271 into Ala. The upper band represents autophosphorylated MK5, while the lower band is phosphorylated SEPT8. Relative densitometry units (RDU) of the bands representing phosphorylated SEPT8 are shown. The value obtain for wild-type SEPT8 was arbitrary set as 1.0 and the other values were related to this.

the latter on phosphoSEPT8 levels. The double SEPT8 S242A/S271A substitution did not further reduce the phosphorylation levels of SEPT8 (Figure 3C). These findings indicate that Ser-271 and to a lesser extend Ser-242 represent *in vitro* targets for MK5, but that additional amino acid residues can be phosphorylated by MK5 *in vitro*.

#### MK5 colocalizes with SEPT8 in HEK293 and PC12 cells


To examine cellular localization of MK5 with SEPT8, confocal microscopy was performed on HEK293 cells expressing GFP-MK5 and AsRed-SEPT8 fusion proteins separately (Figure 4A) or simultaneously (Figure 4B). As previously reported, GFP-MK5 protein resides predominantly in the nucleus, but can also be detected in the cytoplasm<sup>[38]</sup>, while The RFP-SEPT8 protein is exclusively located in the cytoplasm (Figure 4A). Cotransfection with expression plasmid encoding tagged MK5 and SEPT8 demonstrated colocalization of these two proteins in the perinuclear area (Figure 4B). Several studies have shown the involvement of septins in neuronal transmission and exocytosis. Therefore, we wanted to test if a similar colocalization pattern of proteins could be seen in neuroendocrine PC12 cells. Colocalization was observed not only in cell bodies but also in neurite terminals of PC12 cells (Figure 4C). Interestingly, a previous study showed that SEPT5 was concentrated near the plasma membrane and in growth cones of PC12 cells<sup>[45]</sup>.

#### MK5 and SEPT8 colocalize with synaptophysin in the neuroblastoma cell line SK-N-DZ

In a previous study, SEPT8 colocalized with the synaptic marker synaptophysin<sup>[36]</sup>. To examine the cellular localization of SEPT8 with synaptophysin in the neuroblastoma cell line SK-N-DZ, cells were transfected with AsRed-SEPT8. Protein was visualized directly, and anti-synaptophysin FITC conjugate antibodies were used to monitor synaptophysin localization. SEPT8 and synaptophysin showed strong colocalization (Figure 5A), confirming the findings by Ito and colleagues<sup>[36]</sup>. We then investigated whether MK5 could colocalize with synaptophysin because we had observed colocalization with SEPT8 in several cell lines. Indeed, MK5 colocalized with synaptophysin in a similar fashion as SEPT8 (Figure 5B).

## DISCUSSION


Several genuine substrates have been identified for MK5 including ERK3, ERK4, 14-3-3 $\epsilon$ , p53, Rheb and Hsp27<sup>[6,8,10-15]</sup>. However, the functions of MK5 remain elusive, and MK5-deficient mice appear normal or die at embryonic stage E11.5, depending on the genetic background of the mice<sup>[6,10,46]</sup>. In our search for other possible MK5 interaction partners that may provide a clue to the biological functions of MK5, we have identified SEPT8 as an *in vitro* MK5 substrate. The interaction was originally revealed by



**Figure 4 Mitogen-activated protein kinase-activated protein kinase 5 colocalizes with SEPT8.** A: HeLa cells were transfected separately with an expression plasmid for GFP-mitogen-activated protein kinase-activated protein kinase 5 (MK5) (left panel) or AsRed-SEPT8 (right panel); B: HeLa cells cotransfected with both expression plasmids. The subcellular localization of RFP-tagged SEPT8 (left panel), GFP-tagged MK5 (middle panel), or both proteins (merged; right panel) is shown; C: PC12 cells cotransfected with expression vectors for AsRed-SEPT8 (left panel) and GFP-MK5 (middle panel). Colocalization is shown in the right panel; D: Enlargement of the areas marked by arrows in figures (C) shows clear colocalization of MK5 and SEPT8. After 24 h, cells were fixed and MK5 (green channel) and SEPT8 (red channel) were visualized directly.

yeast-two hybrid assay and confirmed in mammalian cell cultures by coimmunoprecipitation, GST pull-down and FRET assays. Moreover, colocalization of both proteins

was observed in different cell lines transfected with expression plasmids for GFP-MK5 and AsRed-SEPT8 fusion. We went on to investigate whether MK5 had kinase



**Figure 5 Mitogen-activated protein kinase-activated protein kinase 5 and SEPT8 colocalize with synaptophysin.** A: SK-N-DZ cells were transfected with expression vector encoding AsRed-SEPT8 and after 24 h, cells were fixed. Synaptophysin was visualized by staining with anti-synaptophysin fluorescein isothiocyanate (FITC) conjugate antibody (left panels), while AsRed-SEPT8 was visualized directly (red channel; middle panels). A merged image of red and green channels is shown in the right panel; B: SK-N-DZ cells were fixed and stained with anti-synaptophysin FITC conjugate antibody (left panel) and with anti-PRAK antibody followed by Alexa Fluor 568 anti-rabbit antibody (middle panel). Merged image of red and green channels is shown in the right panel.

activity towards SEPT8 and it appeared that SEPT8 was indeed phosphorylated by MK5 *in vitro*. To the best of our knowledge, this is the first report linking MAPK-activated protein kinases to the group of septin proteins. However, previous studies have identified several mammalian septins as substrates of several kinases. For instance, SEPT1 has been shown to be phosphorylated *in vitro* by aurora-B kinase<sup>[41]</sup>. SEPT2 is a substrate of casein kinase 2, and its phosphorylation on Ser-218 is crucial for the proliferation of hepatoma carcinoma cells<sup>[44]</sup>. Moreover, SEPT2 is also an *in vitro* substrate for protein kinase (PK)C and cAMP-dependent PKA<sup>[47]</sup>. SEPT3 phosphorylation on Ser-91 by cGMP-dependent PKG may contribute to the regulation of its subcellular localization in neurons<sup>[40]</sup>. SEPT5 phosphorylation by cyclin-dependent kinase 5 at Ser-17 and Ser-327 reduces binding of septin to syntaxin, therefore

playing a role in modulating exocytic secretion<sup>[42,43]</sup>. MK5 phosphorylates SEPT8 on Ser-271 and with lower stoichiometry on Ser-242 in an *in vitro* assay. The double SEPT8 S242A/S271A mutant is still phosphorylated *in vitro*, indicating that other sites may act as MK5 phosphoacceptor sites *in vitro*. Both sites are conserved in SEPT8 from different species ranging from fish to humans (Figure 6). This indicates that the sites are crucial for normal function of SEPT8. It remains to be tested whether MK5 can phosphorylate these sites *in vivo*. Phosphoproteomic studies have demonstrated that SEPT8 is phosphorylated on Ser-10 and Ser-141 in mouse brain, mouse skin melanoma, and nocodazole-arrested HeLa cells<sup>[48-50]</sup>. Both sites are conserved in fish, amphibians, and several mammals such as apes, primates, rodents and cattle. The protein kinases responsible for these phosphorylations have not

```

Human (NP_00109228.1)      TRIHVCLYFITPTGH6SLKSLDLVMTMKKLDKSVNIIPIAKADTIS6KSELHKFKIKIMGEL
Armadillo (ACQ63032.1)    *****
Baboon (NP_001162506.1)   *****
Cattle (AAI20075.1)       *****
Chicken (XP_414648.3)     *****S*
Chimpanzee (XP_517927.3)  *****
Dog (XP_5319034)         *****
Dusky titi (B1MTN8.1)    *****
Dwarf hamster (EGW03012.1) *****
Elephant (XP_003404794.1) *****
Ferret (AER93422.1)      *****
Gibbon (XP_003259994.1)  *****
Guinea pig (XP_003464551.1) *****
Horse (XP_001504480.3)   **V*****
Horseshoe bat (B2KIE9.1) **V*****
Lancelet (XP_002588303.1) **V*A*****N*****S*
Lizard (XP_003217450.1) *****N*****S*
Macaque (BAE87336.1)    *****
Marmoset (XP_002744650.1) *****
Mouse (CAP19147.1)      *****
Naked mole rat (EHB07406.1) *****
Nile tilapia (XP_003447038) *****
Opossum (XP_003339562.1) *****S*S
Orangutan (XP_002815929.1) *****
Panda (XP_002913002.1)  **V*****V*****
Pig (XP_003123974.1)    *****
Platypus (XP_001510590.2) *****
Puffer fish (CAG11702.1) *****I*S*
Rabbit (NP_001164820.1) *****
Rat (NP_001100472.1)    *****
Salmon (NP_001167234.1)  G*V*I*****A*****S*
Turkey (XP_003210544.1) *****S*
Xenopus (NP_001087375.1) S*****S*
Zebra finch (XP_002188929) *****S*
Zebrafish (NP_001108589) *****S*

```

**Figure 6 Mitogen-activated protein kinase-activated protein kinase 5 phosphoacceptor sites in human SEPT8 are conserved in SEPT8 from other species.** Alignment of proven and putative SEPT8 proteins in different species of the region encompassing mitogen-activated protein kinase-activated protein kinase 5 phosphoacceptor sites Ser-242 and Ser-271 (numbering for human SEPT8). The code in parenthesis refers to the accession number in the Protein database (<http://www.ncbi.nlm.nih.gov/protein/>). Asterisk indicates identical amino acid residues. The non-conserved residues are shown in red. The one-letter amino acid code is used. The residues corresponding to human SEPT8 Ser-242 and Ser-271 are shown.

been identified. Our *in vitro* kinase assay with the peptide array did not indicate that Ser-10 and Ser-141 are *in vitro* phosphorylation sites for MK5.

The biological implications of MK5-mediated phosphorylation of SEPT8 are not known but it may affect structural properties by interfering with di- and trimeric complex formation with other septins. It has been shown for SEPT7 that substitution of tyrosine-318 into non-phosphorylatable Ala prevents interaction with SEPT8<sup>[30]</sup>. Phosphorylation of SEPT8 may have a similar effect on complex formation with septins. Phosphorylation may also affect the role of SEPT8 in cellular functions. The exact functions of SEPT8 remain to be elucidated. In accordance with SEPT5, SEPT8 is implicated in vesicular transport and exocytosis processes of neurotransmitter release and platelet secretion. In neurons, SEPT5 binds syntaxin, one of the SNARE proteins, and copurifies with synaptic vesicles, suggesting a role in exocytosis and synaptic vesicle dynamics<sup>[33,45,51]</sup>. Platelets from *SEPT5*<sup>-/-</sup> mice possess altered serotonin secretion and aggregation<sup>[25]</sup>. SEPT8 expression is high in neurons and platelets, and a recent study has suggested the importance of SEPT8 in the process of SNARE complex formation and subsequent neurotransmitter release, but actual experimental

proof is lacking<sup>[32,34,36,45,52]</sup>. Moreover, SEPT8 colocalizes with the synaptic marker synaptophysin in primary cultured rat hippocampal neurons<sup>[56]</sup>. We also observed colocalization of MK5 and synaptophysin in neuroblastoma SK-N-DZ cells. MAPK p38, which can act as an upstream activator of MK5<sup>[53]</sup>, has been shown to be involved in SNARE-dependent exocytotic release of brain-derived neurotrophic factor from microglia<sup>[54]</sup>. Finally, transgenic mice overexpressing an active variant of MK5 display different anxiety-related traits as compared to wild-type littermates<sup>[5]</sup>. All these observations point to a possible role of MK5 in exocytosis that may comprise SEPT8.

## ACKNOWLEDGMENTS

The authors thank Dr. Koh-Ichi Nagata and Dr. Masaki Inagaki for the kind gift of SEPT8 expression plasmid, Dr. Terje Johansen for the generous gift of the Gateway destination vectors pDest-EYFP and pDest-ECFP, Kenneth Larsen (Bioimaging platform, University of Tromsø) for help with the confocal microscope, Marte Singås Dragset for assistance with cloning, and Dr. Ole Rumohr Blingsmo and Dr. Elisa Bjørge (Biotechnology Centre, Oslo, Norway) for synthesis and valuable suggestions with peptide arrays.

## COMMENTS

**Background**

The mitogen-activated protein kinase (MAPK) pathways transmit signals through a cascade of phosphorylation events, thereby controlling cellular processes such as proliferation, differentiation, migration, survival/apoptosis, and gene regulation. The precise function of one of the MAPKs, MAPK-activated protein kinase 5 (MK5), remains elusive. The aim of this study was to identify new substrates for MK5 in an effort to better understand the function of this protein kinase.

**Research frontiers**

Phosphorylation of proteins at serine, threonine and tyrosine residues by protein kinases is an important post-translational modification that controls the activity of the substrates. The human genome encodes more than 500 different protein kinases, including a large group known as MAPKs. MAPKs control through phosphorylation of their substrates crucial cellular processes. Perturbed action of these kinases can lead to malignant and nonmalignant diseases. It is therefore important to divulge the exact functions and genuine substrates of these kinases. This may allow designing therapeutic strategies for pathological conditions in which MAPKs play a causal role.

**Innovations and breakthroughs**

The genuine function of MK5 remains incompletely understood because few genuine substrates have been characterized. This study identified septin 8 as a novel interaction partner for MK5 and is the first to demonstrate that MAPKs can phosphorylate a member of the septin family. Septins are small GTP-binding proteins that participate in processes ranging from cytoskeletal architecture, scaffolding, cytokinesis, ciliogenesis, and neurogenesis. The function of septin 8 remains enigmatic, but it is enriched at presynapses and interacts with several proteins of synaptic vesicles. Hence, septin 8 may be involved in neurotransmitter release and the role of septin 8 may be modulated by MK5-mediated phosphorylation. Interestingly, transgenic mice overexpressing a constitutive active variant of MK5 showed changes in anxiety-related behavior.

**Applications**

Compounds that specifically modify the phosphorylation of septin 8 by modulating the activity of MK5 or that interfere with the interaction between MK5 and septin 8 may have an impact on neuronal secretion and as such be used in patients suffering from perturbed neurosecretion.

**Peer review**

Overall, this is a potentially interesting paper; however, the data presented are preliminary.

## REFERENCES

- 1 New L, Jiang Y, Zhao M, Liu K, Zhu W, Flood LJ, Kato Y, Parry GC, Han J. PRAK, a novel protein kinase regulated by the p38 MAP kinase. *EMBO J* 1998; **17**: 3372-3384
- 2 Ni H, Wang XS, Diener K, Yao Z. MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated protein kinase, is a substrate of the extracellular-regulated kinase (ERK) and p38 kinase. *Biochem Biophys Res Commun* 1998; **243**: 492-496
- 3 Gaestel M. MAPKAP kinases - MKs - two's company, three's a crowd. *Nat Rev Mol Cell Biol* 2006; **7**: 120-130
- 4 Gerits N, Mikalsen T, Kostenko S, Shiryayev A, Johannessen M, Moens U. Modulation of F-actin rearrangement by the cyclic AMP/cAMP-dependent protein kinase (PKA) pathway is mediated by MAPK-activated protein kinase 5 and requires PKA-induced nuclear export of MK5. *J Biol Chem* 2007; **282**: 37232-37243
- 5 Gerits N, Van Belle W, Moens U. Transgenic mice expressing constitutive active MAPKAPK5 display gender-dependent differences in exploration and activity. *Behav Brain Funct* 2007; **3**: 58
- 6 Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, Xie C, Chen J, Deng Q, Yamout M, Dong MQ, Frangou CG, Yates JR, Wright PE, Han J. PRAK is essential for ras-induced senescence and tumor suppression. *Cell* 2007; **128**: 295-308
- 7 Kostenko S, Dumitriu G, Læg Reid KJ, Moens U. Physiological roles of mitogen-activated-protein-kinase-activated p38-regulated/activated protein kinase. *World J Biol Chem* 2011; **2**: 73-89
- 8 Zheng M, Wang YH, Wu XN, Wu SQ, Lu BJ, Dong MQ, Zhang H, Sun P, Lin SC, Guan KL, Han J. Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1. *Nat Cell Biol* 2011; **13**: 263-272
- 9 Yoshizuka N, Chen RM, Xu Z, Liao R, Hong L, Hu WY, Yu G, Han J, Chen L, Sun P. A novel function of p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis. *Mol Cell Biol* 2012; **32**: 606-618
- 10 Schumacher S, Laass K, Kant S, Shi Y, Visel A, Gruber AD, Kotlyarov A, Gaestel M. Scaffolding by ERK3 regulates MK5 in development. *EMBO J* 2004; **23**: 4770-4779
- 11 Seternes OM, Mikalsen T, Johansen B, Michaelsen E, Armstrong CG, Morrice NA, Turgeon B, Meloche S, Moens U, Keyse SM. Activation of MK5/PRAK by the atypical MAP kinase ERK3 defines a novel signal transduction pathway. *EMBO J* 2004; **23**: 4780-4791
- 12 Aberg E, Perander M, Johansen B, Julien C, Meloche S, Keyse SM, Seternes OM. Regulation of MAPK-activated protein kinase 5 activity and subcellular localization by the atypical MAPK ERK4/MAPK4. *J Biol Chem* 2006; **281**: 35499-35510
- 13 Sun M, Wei Y, Yao L, Xie J, Chen X, Wang H, Jiang J, Gu J. Identification of extracellular signal-regulated kinase 3 as a new interaction partner of cyclin D3. *Biochem Biophys Res Commun* 2006; **340**: 209-214
- 14 Tak H, Jang E, Kim SB, Park J, Suk J, Yoon YS, Ahn JK, Lee JH, Joe CO. 14-3-3epsilon inhibits MK5-mediated cell migration by disrupting F-actin polymerization. *Cell Signal* 2007; **19**: 2379-2387
- 15 Kostenko S, Johannessen M, Moens U. PKA-induced F-actin rearrangement requires phosphorylation of Hsp27 by the MAPKAP kinase MK5. *Cell Signal* 2009; **21**: 712-718
- 16 Li Q, Zhang N, Zhang D, Wang Y, Lin T, Wang Y, Zhou H, Ye Z, Zhang F, Lin SC, Han J. Determinants that control the distinct subcellular localization of p38alpha-PRAK and p38beta-PRAK complexes. *J Biol Chem* 2008; **283**: 11014-11023
- 17 Hartwell LH. Genetic control of the cell division cycle in yeast. IV. Genes controlling bud emergence and cytokinesis. *Exp Cell Res* 1971; **69**: 265-276
- 18 Cao L, Yu W, Wu Y, Yu L. The evolution, complex structures and function of septin proteins. *Cell Mol Life Sci* 2009; **66**: 3309-3323
- 19 Nishihama R, Onishi M, Pringle JR. New insights into the phylogenetic distribution and evolutionary origins of the septins. *Biol Chem* 2011; **392**: 681-687
- 20 Hall PA, Russell SE. Mammalian septins: dynamic heteromers with roles in cellular morphogenesis and compartmentalization. *J Pathol* 2012; **226**: 287-299
- 21 Oh Y, Bi E. Septin structure and function in yeast and beyond. *Trends Cell Biol* 2011; **21**: 141-148
- 22 Kinoshita M. Insight into septin functions from mouse models. In: Hall PA, Russell SE, Pringle JR. The septins. West Sussex: Wiley-Blackwell, 2008: 319-336
- 23 Ono R, Ihara M, Nakajima H, Ozaki K, Kataoka-Fujiwara Y, Taki T, Nagata K, Inagaki M, Yoshida N, Kitamura T, Hayashi Y, Kinoshita M, Nosaka T. Disruption of Sept6, a fusion partner gene of MLL, does not affect ontogeny, leukemogenesis induced by MLL-SEPT6, or phenotype induced by the loss of Sept4. *Mol Cell Biol* 2005; **25**: 10965-10978
- 24 Fujishima K, Kiyonari H, Kurisu J, Hirano T, Kengaku M. Targeted disruption of Sept3, a heteromeric assembly partner of Sept5 and Sept7 in axons, has no effect on developing CNS neurons. *J Neurochem* 2007; **102**: 77-92
- 25 Dent J, Kato K, Peng XR, Martinez C, Cattaneo M, Poujol C, Nurden P, Nurden A, Trimble WS, Ware J. A prototypic platelet septin and its participation in secretion. *Proc Natl Acad Sci USA* 2002; **99**: 3064-3069

- 26 **Ihara M**, Kinoshita A, Yamada S, Tanaka H, Tanigaki A, Kitano A, Goto M, Okubo K, Nishiyama H, Ogawa O, Takahashi C, Itoharu S, Nishimune Y, Noda M, Kinoshita M. Cortical organization by the septin cytoskeleton is essential for structural and mechanical integrity of mammalian spermatozoa. *Dev Cell* 2005; **8**: 343-352
- 27 **Ihara M**, Yamasaki N, Hagiwara A, Tanigaki A, Kitano A, Hikawa R, Tomimoto H, Noda M, Takanashi M, Mori H, Hattori N, Miyakawa T, Kinoshita M. Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. *Neuron* 2007; **53**: 519-533
- 28 **Liu M**, Shen S, Chen F, Yu W, Yu L. Linking the septin expression with carcinogenesis. *Mol Biol Rep* 2010; **37**: 3601-3608
- 29 **Bläser S**, Jersch K, Hainmann I, Zieger W, Wunderle D, Busse A, Zieger B. Isolation of new splice isoforms, characterization and expression analysis of the human septin SEPT8 (KIAA0202). *Gene* 2003; **312**: 313-320
- 30 **Sandroock K**, Bartsch I, Bläser S, Busse A, Busse E, Zieger B. Characterization of human septin interactions. *Biol Chem* 2011; **392**: 751-761
- 31 **Bläser S**, Jersch K, Hainmann I, Wunderle D, Zgaga-Griesz A, Busse A, Zieger B. Human septin-septin interaction: CD-Crel-1 partners with KIAA0202. *FEBS Lett* 2002; **519**: 169-172
- 32 **Bläser S**, Horn J, Würmell P, Bauer H, Strümpell S, Nurden P, Pagenstecher A, Busse A, Wunderle D, Hainmann I, Zieger B. The novel human platelet septin SEPT8 is an interaction partner of SEPT4. *Thromb Haemost* 2004; **91**: 959-966
- 33 **Beites CL**, Campbell KA, Trimble WS. The septin Sept5/CD-Crel-1 competes with alpha-SNAP for binding to the SNARE complex. *Biochem J* 2005; **385**: 347-353
- 34 **Zhang Y**, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. *Proc Natl Acad Sci USA* 2000; **97**: 13354-13359
- 35 **Martínez C**, Sanjuan MA, Dent JA, Karlsson L, Ware J. Human septin-septin interactions as a prerequisite for targeting septin complexes in the cytosol. *Biochem J* 2004; **382**: 783-791
- 36 **Ito H**, Atsuzawa K, Morishita R, Usuda N, Sudo K, Iwamoto I, Mizutani K, Katoh-Semba R, Nozawa Y, Asano T, Nagata K. Sept8 controls the binding of vesicle-associated membrane protein 2 to synaptophysin. *J Neurochem* 2009; **108**: 867-880
- 37 **Nagata K**, Inagaki M. Cytoskeletal modification of Rho guanine nucleotide exchange factor activity: identification of a Rho guanine nucleotide exchange factor as a binding partner for Sept9b, a mammalian septin. *Oncogene* 2005; **24**: 65-76
- 38 **Seternes OM**, Johansen B, Hegge B, Johannessen M, Keyse SM, Moens U. Both binding and activation of p38 mitogen-activated protein kinase (MAPK) play essential roles in regulation of the nucleocytoplasmic distribution of MAPK-activated protein kinase 5 by cellular stress. *Mol Cell Biol* 2002; **22**: 6931-6945
- 39 **Huston E**, Lynch MJ, Mohamed A, Collins DM, Hill EV, MacLeod R, Krause E, Baillie GS, Houslay MD. EPAC and PKA allow cAMP dual control over DNA-PK nuclear translocation. *Proc Natl Acad Sci USA* 2008; **105**: 12791-12796
- 40 **Xue J**, Milburn PJ, Hanna BT, Graham ME, Rostas JA, Robinson PJ. Phosphorylation of septin 3 on Ser-91 by cGMP-dependent protein kinase-I in nerve terminals. *Biochem J* 2004; **381**: 753-760
- 41 **Qi M**, Yu W, Liu S, Jia H, Tang L, Shen M, Yan X, Saiyin H, Lang Q, Wan B, Zhao S, Yu L. Septin1, a new interaction partner for human serine/threonine kinase aurora-B. *Biochem Biophys Res Commun* 2005; **336**: 994-1000
- 42 **Taniguchi M**, Taoka M, Itakura M, Asada A, Saito T, Kinoshita M, Takahashi M, Isobe T, Hisanaga S. Phosphorylation of adult type Sept5 (CDCrel-1) by cyclin-dependent kinase 5 inhibits interaction with syntaxin-1. *J Biol Chem* 2007; **282**: 7869-7876
- 43 **Amin ND**, Zheng YL, Kesavapany S, Kanungo J, Guszczynski T, Sihag RK, Rudrabhatla P, Albers W, Grant P, Pant HC. Cyclin-dependent kinase 5 phosphorylation of human septin SEPT5 (hCDCrel-1) modulates exocytosis. *J Neurosci* 2008; **28**: 3631-3643
- 44 **Yu W**, Ding X, Chen F, Liu M, Shen S, Gu X, Yu L. The phosphorylation of SEPT2 on Ser218 by casein kinase 2 is important to hepatoma carcinoma cell proliferation. *Mol Cell Biochem* 2009; **325**: 61-67
- 45 **Beites CL**, Xie H, Bowser R, Trimble WS. The septin CD-Crel-1 binds syntaxin and inhibits exocytosis. *Nat Neurosci* 1999; **2**: 434-439
- 46 **Shi Y**, Kotlyarov A, Laabeta K, Gruber AD, Butt E, Marcus K, Meyer HE, Friedrich A, Volk HD, Gaestel M. Elimination of protein kinase MK5/PRAK activity by targeted homologous recombination. *Mol Cell Biol* 2003; **23**: 7732-7741
- 47 **Xue J**, Wang X, Malladi CS, Kinoshita M, Milburn PJ, Lengyel I, Rostas JA, Robinson PJ. Phosphorylation of a new brain-specific septin, G-septin, by cGMP-dependent protein kinase. *J Biol Chem* 2000; **275**: 10047-10056
- 48 **Beausoleil SA**, Villén J, Gerber SA, Rush J, Gygi SP. A probability-based approach for high-throughput protein phosphorylation analysis and site localization. *Nat Biotechnol* 2006; **24**: 1285-1292
- 49 **Trinidad JC**, Thalhammer A, Specht CG, Lynn AJ, Baker PR, Schoepfer R, Burlingame AL. Quantitative analysis of synaptic phosphorylation and protein expression. *Mol Cell Proteomics* 2008; **7**: 684-696
- 50 **Zanivan S**, Gnad F, Wickström SA, Geiger T, Macek B, Cox J, Fässler R, Mann M. Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. *J Proteome Res* 2008; **7**: 5314-5326
- 51 **Beites CL**, Peng XR, Trimble WS. Expression and analysis of properties of septin CDCrel-1 in exocytosis. *Methods Enzymol* 2001; **329**: 499-510
- 52 **Hsu SC**, Hazuka CD, Roth R, Foletti DL, Heuser J, Scheller RH. Subunit composition, protein interactions, and structures of the mammalian brain sec6/8 complex and septin filaments. *Neuron* 1998; **20**: 1111-1122
- 53 **Shiryayev A**, Moens U. Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: ménage à trois or ménage à quatre? *Cell Signal* 2010; **22**: 1185-1192
- 54 **Trang T**, Beggs S, Wan X, Salter MW. P2X4-receptor-mediated synthesis and release of brain-derived neurotrophic factor in microglia is dependent on calcium and p38-mitogen-activated protein kinase activation. *J Neurosci* 2009; **29**: 3518-3528

S- Editor Cheng JX L- Editor Kerr C E- Editor Zheng XM

## Acknowledgments to reviewers of *World Journal of Biological Chemistry*

Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of *World Journal of Biological Chemistry*. The editors and authors of the articles submitted to the journal are grateful to the following reviewers for evaluating the articles (including those published in this issue and those rejected for this issue) during the last editing time period.

**Antonio Brunetti, MD, PhD, Professor**, Cattedra di Endocrinologia, Università di Catanzaro "Magna Græcia", 88 100 Catanzaro, Italy

**Wayne Grant Carter, PhD**, School of Biomedical Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, United Kingdom

**Manuel Vazquez-Carrera, Dr.**, University of Barcelona, Unitat de Farmacologia. Facultat de Farmacia. Diagonal 643, Barcelona E-08028, Spain

**Hong-Gang Wang, PhD, Professor**, Lois High Berstler Professor of Pharmacology, Penn State College of Medicine, Penn State Hershey Cancer Institute, CH74, 500 University Drive, PO Box 850, Hershey, PA 17033-0850, United States

**Events Calendar 2012**

January 10, 2012

Annual Symposium-Frontiers in  
Biological Catalysis  
Cambridge, United Kingdom

February 1-2, 2012

World Cancer Metabolism Summit  
Washington DC, WA 33601,  
United States

February 10-11, 2012

2012-Indo-Korean Conference on  
Integrative Bioscience Research-  
Opportunities and Challenges  
Coimbatore, India

February 12, 2012

4th International Conference on  
Drug Discovery and Therapy  
Dubai, United Arab Emirates

February 19, 2012

Applied Pharmaceutical  
Analysis-India  
Ahmedabad, India

February 20, 2012

International Conference and  
Exhibition on Metabolomics and  
Systems Biology  
San Francisco, CA 95101,  
United States

February 20, 2012

Healthcare India 2012  
New Delhi, India

February 20, 2012

Metabolomics2012  
Burlingame, CA 95101, United States

February 24, 2012

19th Annual Southeastern Regional

Yeast Meeting 2012

Atlanta, GA 30314, United States

March 2-5, 2012

Medicinal Chemistry Conference  
2012  
Lanzarote, Spain

March 12, 2012

Vaccine World Summit  
Hyderabad, India

March 13, 2012

ADME and Predictive Toxicology  
Munich, Germany

March 19-22, 2012

Society for Endocrinology: BES 2012  
Harrogate, United Kingdom

March 26-27, 2012

Intrinsically disordered proteins  
York, United Kingdom

March 27, 2012

RNAi2012: Gene Regulation by  
Small RNAs  
Oxford, United Kingdom

March 28, 2012

LRRK2: Function and dysfunction  
London, United Kingdom

March 28, 2012

Advances in Microarray Technology  
Conference and Exhibition  
Riccarton, United Kingdom

April 16, 2012

Biologics World Korea  
Seoul, South Korea

April 23, 2012

Flow Chemistry Congress and  
Exhibition

Boston, MA 02110, United States

United States

April 25, 2012

European Algae Biomass  
London, United Kingdom

April 30-May 03, 2012

Association for Clinical Biochemistry  
2012  
Liverpool, United Kingdom

May 5-9, 2012

15th International and  
14th European Congress of  
Endocrinology  
Florence, Italy

May 7-8, 2012

LIPID MAPS Annual Meeting  
2012: Impact on Cell Biology,  
Metabolomics and Translational  
Medicine  
La Jolla, CA 92093, United States

May 16, 2012

18th Annual International Stress  
and Behavior Neuroscience and  
Biopsychiatry Conference (North  
America)  
Petersburg, FL 33063,  
United States

June 11, 2012

Rab GTPases and their interacting  
proteins in health and disease  
Cork, Ireland

July 8-13, 2012

Biocatalysis  
Smithfield, RI 02896, United States

July 15-19, 2012

2012 AACC Annual Meeting  
Los Angeles, CA 90015,

August 5-10, 2012

Medicinal Chemistry  
New London, NH 03257,  
United States

August 18, 2012

The 30th World Congress of  
Biomedical Laboratory Science  
Berlin, Germany

August 18-22, 2012

The 30th World Congress of  
Biomedical Laboratory Science  
Berlin, Germany

August 25-29, 2012

9th International Symposium on  
Biomolecular Chemistry  
Beijing, China

September 2-6, 2012

22nd International Symposium on  
Medicinal Chemistry  
Berlin, Germany

September 11-13, 2012

Lipids and Membrane Biophysics  
London, United Kingdom

September 16, 2012

15th International Biotechnology  
Symposium  
Daegu, South Korea

September 25, 2012

Molecular Diagnostics World  
Congress and Exhibition  
San Diego, CA 09963, United States

November 5-9, 2012

7th International IUPAC Symposium  
on Mycotoxins and Phycotoxins  
Rotterdam, Netherlands

## GENERAL INFORMATION

*World Journal of Biological Chemistry* (*World J Biol Chem, WJBC*, online ISSN 1949-8454, DOI: 10.4331), is a monthly, open-access (OA), peer-reviewed journal supported by an editorial board of 529 experts in biochemistry and molecular biology from 40 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e., the maximization of the value to the readers, authors and society.

### Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJBC* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article via online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJBC* is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJBC* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality articles, thereby

realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

### Aims and scope

The major task of *WJBC* is to rapidly report the most recent developments in the research by the close collaboration of biologists and chemists in area of biochemistry and molecular biology, including: general biochemistry, pathobiochemistry, molecular and cellular biology, molecular medicine, experimental methodologies and the diagnosis, therapy, and monitoring of human disease.

### Columns

The columns in the issues of *WJBC* will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systemically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Articles: To report innovative and original findings in biochemistry and molecular biology; (9) Brief Articles: To briefly report the novel and innovative findings in biochemistry and molecular biology; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in *WJBC*, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of biochemistry and molecular biology; and (13) Guidelines: To introduce Consensus and Guidelines reached by international and national academic authorities worldwide on the research in biochemistry and molecular biology.

### Name of journal

*World Journal of Biological Chemistry*

### ISSN

ISSN 1949-8454 (online)

### Editor-in-chief

**Yin-Yuan Mo, PhD, Associate Professor**, Medical Microbiology, Immunology and Cell Biology, Southern Illinois University School of Medicine, Springfield, IL 62702, United States

### Editorial office

*World Journal of Biological Chemistry*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381892  
Fax: +86-10-85381893  
E-mail: [wjbc@wjgnet.com](mailto:wjbc@wjgnet.com)  
<http://www.wjgnet.com>

## Instructions to authors

### **Indexed and abstracted in**

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

### **Published by**

Baishideng Publishing Group Co., Limited

---

## **SPECIAL STATEMENT**

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### **Biostatistical editing**

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### **Conflict-of-interest statement**

In the interests of transparency and to help reviewers assess any potential bias, *WJBC* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### **Statement of informed consent**

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### **Statement of human and animal rights**

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional

review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

---

## **SUBMISSION OF MANUSCRIPTS**

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### **Online submissions**

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/1949-8454office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/1949-8454/g\\_info\\_20100316155305.htm](http://www.wjgnet.com/1949-8454/g_info_20100316155305.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjbc@wjgnet.com](mailto:wjbc@wjgnet.com), or by telephone: +86-10-85381892. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

---

## **MANUSCRIPT PREPARATION**

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

### **Title page**

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the

standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381892 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJBC*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

### Abstract

There are unstructured abstracts (no less than 256 words) and structured abstracts (no less than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no less than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/..."; MATERIALS AND METHODS (no less than 140 words); RESULTS (no

less than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ; CONCLUSION (no more than 26 words).

### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: [http://www.wjgnet.com/1949-8454/g\\_info\\_20100316160646.htm](http://www.wjgnet.com/1949-8454/g_info_20100316160646.htm).

### Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, <sup>c</sup>*P* < 0.05 and <sup>d</sup>*P* < 0.01 are used. A third series of *P* values can be expressed as <sup>e</sup>*P* < 0.05 and <sup>f</sup>*P* < 0.01. Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals ac-

## Instructions to authors

ording to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarrhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ*

2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS A Careaction* 2002; 1-6 [PMID: 12154804]

### Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

### Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as  $\nu$  (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

### Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose) = 6.4  $\pm$  2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5  $\mu$ g/L; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, etc. Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantumms can be found at: [http://www.wjgnet.com/1949-8454/g\\_info\\_20100309232449.htm](http://www.wjgnet.com/1949-8454/g_info_20100309232449.htm).

### Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

### Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, etc.

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, etc.

Biology: *H. pylori*, *E. coli*, etc.

### Examples for paper writing

**Editorial:** [http://www.wjgnet.com/1949-8454/g\\_info\\_20100316155524.htm](http://www.wjgnet.com/1949-8454/g_info_20100316155524.htm)

**Frontier:** [http://www.wjgnet.com/1949-8454/g\\_info\\_20100312091506.htm](http://www.wjgnet.com/1949-8454/g_info_20100312091506.htm)

**Topic highlight:** [http://www.wjgnet.com/1949-8454/g\\_info\\_20100316155725.htm](http://www.wjgnet.com/1949-8454/g_info_20100316155725.htm)

**Observation:** [http://www.wjgnet.com/1949-8454/g\\_info\\_20100316155928.htm](http://www.wjgnet.com/1949-8454/g_info_20100316155928.htm)

**Guidelines for basic research:** [http://www.wjgnet.com/1949-8454/g\\_info\\_20100312092119.htm](http://www.wjgnet.com/1949-8454/g_info_20100312092119.htm)

**Guidelines for clinical practice:** [http://www.wjgnet.com/1949-8454/g\\_info\\_20100312092247.htm](http://www.wjgnet.com/1949-8454/g_info_20100312092247.htm)

**Review:** [http://www.wjgnet.com/1949-8454/g\\_info\\_20100316160234.htm](http://www.wjgnet.com/1949-8454/g_info_20100316160234.htm)

**Original articles:** [http://www.wjgnet.com/1949-8454/g\\_info\\_20100316160646.htm](http://www.wjgnet.com/1949-8454/g_info_20100316160646.htm)

**Brief articles:** [http://www.wjgnet.com/1949-8454/g\\_info\\_20100312092528.htm](http://www.wjgnet.com/1949-8454/g_info_20100312092528.htm)

**Case report:** [http://www.wjgnet.com/1949-8454/g\\_info\\_20100316161452.htm](http://www.wjgnet.com/1949-8454/g_info_20100316161452.htm)

**Letters to the editor:** [http://www.wjgnet.com/1949-8454/g\\_info\\_20100309232142.htm](http://www.wjgnet.com/1949-8454/g_info_20100309232142.htm)

**Book reviews:** [http://www.wjgnet.com/1949-8454/g\\_info\\_20100312092929.htm](http://www.wjgnet.com/1949-8454/g_info_20100312092929.htm)

**Guidelines:** [http://www.wjgnet.com/1949-8454/g\\_info\\_20100312093057.htm](http://www.wjgnet.com/1949-8454/g_info_20100312093057.htm)

## SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Please revise your article according to the revision policies of *WJBC*. The revised version including manuscript and high-resolution image figures (if any) should be re-submitted online (<http://www.wjgnet.com/1949-8454office/>). The author should send the copyright transfer letter, responses to the reviewers, English language Grade B certificate (for non-native speakers of English) and final manuscript checklist to [wjbc@wjgnet.com](mailto:wjbc@wjgnet.com).

### Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

### Copyright assignment form

Please download a Copyright assignment form from [http://www.wjgnet.com/1949-8454/g\\_info\\_20100309233100.htm](http://www.wjgnet.com/1949-8454/g_info_20100309233100.htm).

### Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/1949-8454/g\\_info\\_20100309232833.htm](http://www.wjgnet.com/1949-8454/g_info_20100309232833.htm).

### Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

### Links to documents related to the manuscript

*WJBC* will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

### Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

### Publication fee

*WJBC* is an international, peer-reviewed, Open-Access, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. The related standards are as follows. Publication fee: 1300 USD per article. Editorial, topic highlights, original articles, brief articles, book reviews and letters to the editor are published free of charge.